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Abstract of thesis entitled: 
Baicalein Induces Caspase-dependent Apoptosis in 
Human Melanoma A375 Cells Associated with Elicitation of Intrinsic and 
Extrinsic Apoptotic Pathways 
Submitted by LI, Wing Yan Kate 
for the degree of Master of Philosophy in Biology 
at The Chinese University of Hong Kong in September 2007 
Baicalein is a flavone isolated from the dried root of a traditional Chinese 
medicinal herb Scutelleria baicalensis Gorgi, which is used in China for treating 
cancers and inflammatory diseases. However, its mechanism of action has not been 
fully elucidated. In this study, the growth inhibitory effect of baicalein was first 
tested on a panel of cancer cell lines of different histotypes in vitro. Human 
melanoma A375 was then found to be the most responsive cell line, substantiated by 
the lowest IC50 of 37.5 j iM . 
Baicalein exhibited a dose-dependent growth inhibition on the melanoma cells 
first arresting cell cycle at S phase. Apoptosis was then followed, indicated by of the 
cleavage of PARP and DNA fragmentation. Caspase-8, the initiator caspase of the 
extrinsic apoptotic pathway, takes the major role in eliciting the molecular cascade in 
the apoptosis. This is evidenced by its activation at 24 h when PARP cleavage and 
DNA fragmentation was first observed. On the other hand, caspase-9, the initiator 
caspase of the intrinsic mitochondrial pathway, was only activated during the 
iii 
exacerbation phase of apoptosis at 48 h (% of apoptotic c e l l s�20%) . In addition, 
sequential activation from caspase-8 to caspase-3 was illustrated by the inhibition of 
caspase-3 activity after the co-administration of caspase-8 inhibitor, 
Z-IE(OMe)TD(OMe)-FMK with baicalein. Elevation of the death receptors 
TRAIL-R1 (DR4) and TRAIL-R2 (DR5), but not their ligand, TRAIL, was observed, 
which was coherent with the caspase-8 activation. Furthermore, the sensitization of 
the melanoma cells to sub-lethal dose of TRAIL (12.5 ng/ml) was observed after the 
baicalein treatment, possibly due to the elevation of the death receptors. 
Besides the extrinsic death receptor pathway, the intrinsic mitochondrial 
pathway was also found to be activated during the exacerbation phase of apoptosis. 
This is evidenced by mitochondrial membrane depolarization, release of cytochrome 
c from mitochondria into the cytosol, and proteolytic activation of caspase-9. 
Surprisingly, there was no observable change of Bcl-2 family proteins, including 
antiapoptotic Bcl-2 and Bcl-XL； proapoptotic Bax, Bad, BimEL and Bid, which have 
been widely recognized as the central mediators of the intrinsic apoptotic pathway. 
On the other hand, reactive oxygen species (ROS)，which has been reported 
previously to cause mitochondrial dysfunction, was found to be elevated in the 
baicalein-treated cells. Addition of antioxidant Trolox™ was not only able to 
scavenge the ROS produced, but also able to restore the depolarized mitochondrial 
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membrane and release of cytochrome c. 
Findings from this study provide new knowledge about the mechanisms of 
baicalein in controlling cell growth, which is fundamental for the future development 
of this phytochemical as an anticancer regimen. Furthermore, the synergism between 
baicalein and TRAIL may open a new research direction to treat melanoma cells, 
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Chapter 1 
Chapter 1. General Introduction 
1.1 Overview of Cancer 
Every organism comprises of cells. Cell is the basic unit, for single-celled 
organisms like amoeba to complex organisms like human. In order to maintain the 
normal functions of an organism, myriad cellular activities such as proliferation, 
differentiation and cell death, have to be precisely coordinated and monitored (Sears 
and Nevins, 2002). Given the huge amount of events that need to be regulated within 
cells, abnormalities in these processes are not uncommon (Becker et al., 2003). 
In multicellular organisms, homeostasis is maintained through a balance 
between cell proliferation and cell death. The loss of balance of these two events will 
result in abnormal conditions (Thompson, 1995). The imbalance, if not corrected 
properly, eventually leads to the progressive increase in the number of dividing cells, 
forming tumors (neoplasm). Carcinogenesis, a term generally describes the formation 
and development of neoplasia, can be occurred spontaneously or induced by 
carcinogenic agents (Pitot and Dragan，1991). Based on the differences in growth 
patterns, tumors are classified as either benign or malignant. Benign tumor belongs 
to the kind of neoplasm that eventually self-limited in its growth, and lacks of 
capabilities to invade other surrounding or distant tissues, i.e. metastasis (Cotran et 
al., 1999). Contrarily, malignant tumor, also known as cancer, possesses the 
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metastatic ability that moves out form the origin, capable to settle at the endothelium 
of secondary site, extravasating out of the vessels and forming autonomous lesion 
(Egan et aL, 1991). Cancer, the outstanding example of pathological conditions of 
uncontrolled cell growth, is therefore threatening the world population, which more 
than 10 million cases were diagnosed per year globally (Surh, 2003). 
Carcinogenesis is a multistep process that probably results from the action of 
any one or a combination of chemical, physical, biologic, and genetic insults to cells. 
The process of carcinogenesis may be divided into at least three stages: initiation, 
promotion, and progression (Pitot, 1993). As carcinogenesis is a process that 
characterized ultimately by aberrant, uncontrolled cell proliferation, non-lethal DNA 
damage becomes a key requirement for the transformation of normal cells into 
neoplastic cells (Malejka and Tretyakova, 2006). In addition to the presence of DNA 
damage which is either spontaneous or caused by different types of carcinogens, 
defects in DNA repair are also major contributors to malignant transformation. The 
knowledge that differential DNA repair capacity exists is vital to our understanding 
that defects in these repair processes play a vital role in carcinogenesis by increasing 
the rate of mutation and thus the rate of neoplastic progression (Betram, 2000). In the 
molecular aspect of carcinogenesis, cancer-causing genes may belong to either 
oncogenes or tumor suppressor genes, and the initiation of carcinogenesis will be the 
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net effect after the complex interaction between activation of oncogenes and 
inactivation of tumor suppressor genes (Zhivotovsky and Orrenius, 2006). 
Oncogenes are usually derived from normal cellular counterparts, the 
proto-oncogenes, which function as essential components of intracellular signaling 
pathways, for instance, ligands, receptors, molecular switches and cytoplasmic signal 
transducers in a non-mutated state. Activation from proto-oncogenes to oncogenes 
mobilizes signaling cascade and leads to uncontrolled cell proliferation through the 
"change-of-function" mutations (Cline, 1996). Tumor suppressor genes, as the name 
suggested, protect cells from undergoing malignant transformation. Tumor 
suppressor genes function by one of the following mechanisms: protect the genome 
from mutagenic events, impede dysregulated progression through the cell cycle, 
induce apoptosis in cells that escape normal cell cycle controls, and inhibit cellular 
migration and metastasis. Historically, tumor suppressor genes have been described 
to acquire loss of function mutations or deletions leading to their inability to hinder 
malignant transformation (Hayslip and Montero, 2006). The carcinogenic mutations 
found in the two subsets of genes retain and perpetuate in neoplastic cells, most 
likely by the escape from regulatory mechanisms and the defects in DNA repair. This 
allows the accumulation of genetic alterations and thus more severe transformation to 
take place. This marks the state of progression in carcinogenesis. Although malignant 
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tumors are monoclonal in origin, by the time as they progress, metastasize and being 
detectable, the cell population has already become heterogeneous. The heterogeneity 
observed substantiates the significance of multiple alterations accumulated in 
different subclones of cancer cells with different characteristics (Yokota, 2000). 
Taken together, the genes involved in carcinogenesis comprise a specific subset of 
the genome whose products are involved in cellular activities that alter the normality 
of proliferation, such as the progression of a cell through the cell cycle, adhesion of a 
cell to its neighbors, apoptosis, and the repair of DNA damage (Karp, 2003). 
Regarding to the genome instability in carcinogenesis, restoration of genetic 
alternations back to their normal status represents important clues to re-transform the 
cancer cells back to normal (Aziz et a/.,2003). Beside restoration of genomic 
normality, the elimination of the transformed cells also serve an attractive strategy in 
combating in cancer (Zonig et al., 2001). 
1.2 Apoptosis and cancer 
Apoptosis is also known as programmed cell death. It represents a universal and 
exquisitely efficient cellular suicidal pathway. Apoptosis is a 
genetically-predeposited programme that is essential for embryonic development, 
immune-system function and the maintenance of tissue homeostasis in multicellular 
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organisms (Adams, 2003). Defective apoptotic pathways disrupt the balance between 
cell proliferation and cell death and thus lead to disease like cancer (Fesik, 2005). 
Apoptosis is generally characterized by distinct morphological characteristics and 
energy-dependent biochemical mechanisms (Elmore, 2007). Morphologically, 
apoptotic cells generally display characteristics such as cell shrinkage, cytoplasmic 
condensation, chromatin segregation and condensation, membrane blebbing, and the 
formation of membrane-bound apoptotic bodies (Loo and Rillema，1998). The 
dissembled materials are packed inside the apoptotic bodies for subsequent 
engulfment by neighbouring cells and phagocytes, thus preventing unnecessary 
inflammatory response (Savill and Fadok, 2000). The morphological characteristics 
can be observed at different stage of apoptosis, and the detections of these changes 
have become solid evidence of apoptosis. The morphological changes are in fact 
resulted from the intrinsic biochemical changes that occur within apoptotic cells, 
such as DNA fragmentation and caspase activation. Caspases, or cysteine 
aspartyl-specific proteases, are the proteases that participate in the demolition 
process of apoptotic cells. The executioner caspases (caspase-3, -6 and -7) are 
ultimately responsible for the breaking down of cellular substrates, yet they needed 
to be first proteolytically activated by initiator caspases (caspase-8 and -9) 
(Thornberry, 1998; Adams, 2003). Apoptosis can be initiated by two major pathways: 
5 
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involving either the release of cytochrome c in the mitochondria (the intrinsic 
mitochondrial pathway), or mediating by the activation of death receptors which 
sense the death signals by the binding with death-inducing ligands (the extrinsic 
death receptor pathway) (Broker et al., 2005). Both branches of apoptosis will be 
discussed in detail section 1.3a and 1.3b. Although the involvement of caspases has 
been regarded as an indispensable feature in apoptosis, more and more recent studies 
have demonstrated that caspase-independent apoptosis also played a role in 
eliminating unwanted cells in an organism. In the absence of caspase-activation, 
apoptosis can also be executed via the actions of other proteases that could also elicit 
apoptosis-like cell death (Stoka et al., 2001). The discovery of various models of 
apoptosis opens an alternative research direction in the cell death pathways of cancer 
(Broker et al., 2005), which will not be discussed here. 
Myriad studies have shown that many types of cancers are defective in eliciting 
the apoptotic pathway. The evasion of apoptosis has been regarded as one of the six 
hallmarks of cancer that endows the cancer cells with ability of uncontrolled growth 
and metastasis (Debatin and Krammer, 2004; Hanahan and Weinberg, 2000). For 
instance, the tumor suppressor protein p53 is often mutated in many types of cancer. 
Accumulation of the wild-type p53 protein in the cell results in upregulation of 
apoptosis or cell cycle arrest related proteins (Hailfmger et al., 2007). It is therefore 
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not surprising that cancer cells are having mutated or even deleted expression ofp53. 
Another common apoptosis-related defects found in cancer cells would be the 
overexpression of a protein called Bcl-2. Bcl-2 is an antiapoptotic protein that 
facilitates survival of cells (details in section 1.3.2.i). Overexpression of Bcl-2 is 
commonly found in metastatic tumors, including breast (Lee et al., 2007) and colon 
(Li et al., 2007) carcinomas. Therefore, agents that are able to restore the normality 
of apoptotic pathway in cancer cells have the potential for effectively treating cancer, 
either use as a therapeutic drug or adjuvant therapy. 
1.3. Roles and regulations of caspase-dependent apoptosis 
Caspases are a family of cysteine proteases that cleave their substrates 
specifically following an aspartate residue (Thornberry and Labzenik, 1998; Kumar, 
2007). Fourteen caspases have been identified in mammalian cells, of which 11 
enzymes are known in humans (Lamkanfi et al, 2002). These enzymes are 
synthesized as precursor inactive zymogens that, upon receiving apoptotic signals, 
proteolytically process to generate subunits containing the active enzymes (Degterev 
et al., 2003). Recent studies have revealed that the cleavage of the zymogen is not 
always a forcible requirement for caspase activation, but all activated caspases can be 
detected as cleaved fragments in apoptotic cells (Degterev et al., 2003; Fuentes-Prior 
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and Salvesen, 2004). The caspase-dependent apoptotic cascade basically involves 
two subtypes of caspases: the initiator caspases (caspase-2, -8, -9 and -10) that 
activate the downstream effector caspases (caspase-3, -6 and -7) which are 
responsible for the direct destruction of cellular materials. From the two subsets, 
caspase-9 is regarded as the leading caspase in the intrinsic mitochondrial pathway; 
whereas caspase-8 is the key initiator of death-receptor-mediated apoptosis (Kumar, 
2007). Other enzymes (caspase-1, -4，-5，-11, -12 and -14) are mainly involved in 
cytokine maturation and inflammation (Vermeulen et al., 2005; Chang and Yang, 
2000). By the action of caspases, two apoptotic pathways can be triggered: the 
extrinsic death-receptor pathway and the intrinsic mitochondrial pathway. 
1.3.1 Extrins ic death receptor pathway 
The extrinsic apoptotic pathway is activated by the engagement of death 
receptors on the cell surface with their death-inducing ligands. Death receptors are 
members of the tumor necrosis factor (TNF) receptor superfamily. Twenty proteins 
are classified into this family which has broad range of biological functions including 
cell death and survival regulation, differentiation and immunoregulation (Walczak 
and Krammer, 2000). Besides sharing one to four cysteine rich domains (CRDs) 
extracellularly, members of this family also share an 80-amino-acid cytoplasmic 
domain called the 'death domain’，which is of crucial importance in the transmission 
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of death signals to the intracellular signaling cascade (Bossen et al., 2006). Six 
members have been identified in this family including TRAMP (DR3/Apo-3), DR6, 
and the best characterized members of the family CD95 (APO-l/Fas), TNF receptor 
I (TNFRI), TRAIL-R1 (DR4) and TRAIL-R2 (DR5). In order to elicit a cell death 
signal from the cell surface to the cytoplasm, engagement of surface death receptors 
to their corresponding death-inducing ligands is necessary. The TNF family members 
CD95 ligand /FasL, TNFa and TNF-related apoptosis-inducing ligand (TRAIL) are 
the corresponding ligands of the four best characterized receptors mentioned above. 
With some less characterized exceptions, almost all death-inducing ligands are Type 
II transmembrane proteins. The ligands can also exist in free, soluble form by the 
proteolytic action of metalloproteases in the environment (Herr et al,, 2000). They 
function in an autocrine and paracrine manner to mediate the ligation with the 
surface death receptors (Sheikh, and Fornace Jr., 2000). Although ligation between 
death receptor and corresponding ligand is believed to be the activation of extrinsic 
pathway, some evidence has also suggested the possibility of ligand-independent 
activation of death receptors (Sheikh et al, 1998; Peter and Krammer，2003) 
Fig. 1.1 illustrates a simplified diagram of the extrinsic death receptor pathway. 
Upon activation of death receptors by death-inducing ligands, the ligands first 
trimerize to form a trimeric ligand cluster before ligation to corresponding death 
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receptors. The engagement of ligand cluster to death receptor further induces the 
trimerization of death receptors from the original monomeric conformation. Once the 
receptor is activated, the adaptor protein FAS-associated death domain (FADD) will 
then be recruited to the activated receptors via the interactions of there respective 
death domains (Sheikh and Huang, 2004). In case of the TNF-Rl/TNFa death 
receptor-ligand pair, the recruitment of another adaptor protein to the death receptor 
takes place before the recruitment of FADD (Hsu et al., 1995), which will be 
discussed in detail in the next section. Once associated with the death receptor, the 
FADD molecule can further interact with procaspase-8 via the crosslinking between 
the death effector domain (DED) of FADD and procaspase-8 or -10, leading to 
activation of the initiator caspases by oligomerization-mediated activation 
(Askkenazi and Dixit, 1999). The association of the death-inducing ligand, death 
receptor, adaptor protein and initiator caspase forms an active, death inducing 
complex called death-inducing signaling complex (DISC). The DISC formation thus 
activates the downstream caspases and the subsequent apoptotic events by the active 
initiator caspases (Debatin and Krammer, 2004). It can either directly proteolytically 
activate the effector caspase-3 (type I cells) or cleave the carboxy-terminal part of a 
BH3 domain-only proapoptotic member of the Bcl-2 family namely Bid (type II cells) 
(Scaffidi et al., 1999). Consequently, translocation of the truncated Bid (tBid) to the 
10 
mitochondria activates, in combination with Bax, the intrinsic apoptosis pathway 
described in section 1.3 2.i. 
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Fig. 1.1 Schematic diagram showing the components of the extrinsic death 
receptor 
Three well-characterized death-inducing ligands, TNFa, FasL and 
TRAIL, induce death receptor-mediated apoptosis by the ligation to 
their corresponding receptors, recruitment of adaptor proteins and 
initiator caspase. Unlike FasL and TRAIL, TNF« recruits a specific 
adaptor protein, TRADD, prior to the DISC formation. (Modified from 
Sheikh and Fornace Jr., 2000; Sheikh and Huang, 2004) 
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i. TNFR1 and TNFa 
TNFa is protein which exists as a homotrimer in solution. Its bioactivity is 
mainly regulated by soluble TNFa—binding receptors (Bemelmans et al., 1996). 
TNFa acts via two distinct receptors, TNFR1 and TNFR2. However, TNFR1 
manipulates most of the biological activities of TNFa. Therefore, TNFR1 is in fact 
expressed on all cell types, and is capable of inducing apoptotic cell death (van 
Horssen et al., 2006). Besides this apoptotic signaling, TNFR1 also possesses the 
ability to transduce cell survival signals. The TNFR1 -mediated apoptotic signaling is 
elicited firstly by the death receptor-ligand ligation. Upon binding of the homotrimer 
TNFa, the silencer of death domain (SODD) protein will be released and allows 
TNFR1 to trimerize (Sheihk and Huang, 2004), TNFR-associated death domain 
(TRADD) then binds to the death domain of TNFR-1 before recruiting the adaptor 
proteins receptor interacting protein (RIP), TNFR-associated factor 2 (TRAF-2), and 
eventually FADD (Rath and Aggarwal, 1999). FADD then binds to initiator caspases, 
such as procaspase-8, and initiates a protease cascade leading to apoptosis. 
Nonetheless, the involvement of FADD in TNFa-mediated signals transduction 
becomes controversial, as suggested by Jin and El-Deiry (2006). 
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ii. CD95/Fas and. CD95 Ligand/FasL 
Fas and FasL is another well-characterized death-receptor pair in the TNF 
receptor and TNF family. This pair of death receptor-ligand pair has been implicated 
in the maintenance of lymphocyte homeostatsis and immunoregulation. Fas is 
ubiquitously expressed yet FasL expression is only restricted to lymphoid organs and 
immune-privileged tissues (O'connell et al,, 2001). Both the cytokine and its 
receptor can exist in membrane and soluble forms, but only engagement of 
membrane-bound form leads to the activation of caspase-8 via DISC formation 
(Siegel et al., 2000). The Fas/FasL death inducing signaling is very similar to that of 
TNFRl/TNFa, yet on the aspect of FADD recruitment, unlike TNFRl/TNFa, 
Fas/FasL ligation complex directly recruit FADD to form DISC, without recruitment 
of other adaptor proteins (Peter and Krammer, 2003; Sheikh and Huang, 2004). 
Beside this difference, the death signal induction pathway is similar to that of 
TNFRl/TNFa. 
iii. TRAIL-R1 (DR4), TRAIL-R2 (DR5) and TRAIL 
TRAIL and its corresponding receptor DR4 and DR5 is another pair of the 
death-inducing ligand receptor pair. Unlike TNF a and FasL, TRAIL appears to have 
selectivity in triggering apoptosis towards tumor cells, leaving normal tissue 
unaffected (Suliman et al, 2001). The TRAIL resistance observed in normal tissues 
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is postulated to be the expression of TRAIL-R3 (DcRl) and TRAIL-R4 (DcR2), 
which are the decoy receptors of TRAIL that lacks the cytoplasmic death domains 
and thus the ability to induce apoptosis (Zhang et al., 2001). Some of the 
TRAIL-resistant cancer cells were also identified with overexpression of the decoy 
receptors, which compete with the death receptors for TRAIL engagement. The 
phenotypic composition of death and decoy receptors is therefore crucial in 
determining TRAIL sensitivity in cancer cells, which has been previously 
demonstrated in TRAIL-resistant prostate, breast and lung cancer cells (Sanlioglu et 
al., 2007). 
Having longer history than TRAIL, TNFa and Fas have been evidenced to have 
extensive antitumor activity in vitro and has been employed as a potential 
therapeutics in vivo (Ghobrial et al., 2005). Unfortunately, both cytokines possess 
different degrees of toxicity that impair normal physiological functions. 
Recombinant TNFa has proven with extreme toxicity due to vascular inflammatory 
response (Wallach et al., 1999; Zelster et al, 2000). Meanwhile, tumor-derived FasL 
is found to induce severe toxicity in lymphoid organs of the host (Nagarkatti, 2000). 
The differential effects exhibited by the three members of TNF family have 
illustrated that TRAIL is an attractive potential therapeutics that worth-investigating. 
The molecular pathway of activation of DR4 and DR5 is very similar to the Fas 
15 
Chapter 1 
counterpart, which also involves the homotrimer formation of TRAIL, trimerization 
of death receptors, recruitment of FADD and the activation initiator caspases. 
However, the actual activation of death receptor merely depends on the histotypes of 
cancer cells and the type of death receptor inducers (Takeda et al., 2007). For 
instance, sulforaphane can sensitize osteosacroma cells to TRAIL through the 
induction of DR5 expression (Matsui et al., 2006); whereas in renal tumor cells, the 
sensitization towards TRAIL by sub-lethal dose of doxorubicin was due to the 
enhanced expression of DR4 (Jin et al” 2007). It can be appreciated that although 
TRAIL was found to be an efficacious therapeutic in treating cancers, the complexity 
behind the apoptotic mechanisms induced in cancer cells is still awaiting for 
explorations. 
1.3.2 Intrins ic m itochondrial pathway 
Unlike the extrinsic apoptotic pathway which responds primarily towards 
extracellular death signals, the intrinsic apoptotic pathway is triggered by both 
extracellular and intracellular stresses, such as growth-factor withdrawal, hypoxia, 
DNA damage and oncogene induction (Crighton and Ryan, 2005). In response to 
these stress-induced death signals, series of biochemical events are induced 
ultimately in the mitochondria which include permeabilization of the outer 
mitochondrial membrane, the release of cytochrome c and other apoptotic molecules, 
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the formation of apoptosome that comprised of cytochrome c, apoptotic protease 
activating factor 1 (Apaf-1) and caspase-9, as well as caspase activation (Budihardjo 
et al., 1999). As mitochondrial dysfunction and the subsequent release of 
apoptogenic factors mark the “point of no return" in apoptosis (Hangartner, 2000). 
The normal functions and the integrity of the mitochondria should therefore be 
precisely regulated. 
i. Bcl-2 family of proteins 
The Bcl-2 family of proteins has been regarded as the central regulator of 
mitochondrial pathway (Ghobrial et al., 2005). As an important apoptotic regulator, 
this family plays indispensable roles in caspase activation, and its opposing factions 
of anti- and pro-apoptotic members orchestrate the life-or-death decision (Skommer 
et al., 2006). Being categorized in the same family, all proteins in the Bcl-2 family 
contain highly conserved domains, referred to as the Bcl-2 homology (BH) domain 
(BH1-4), which is essential for the homo- and hetero-complex formation among the 
family members that directly affecting the apoptosis-induction capacity. Structural 
and functional analyses revealed that the growing Bcl-2-homologous genes can be 
divided into at least three distinct subfamilies: the Bcl-2 and the Bax subfamily, and 
the BH3-only proteins (Adams and Cory, 1998). 
The Bcl-2 subfamily, including Bcl-2 and its homolog BC1-XL, function as 
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potential oncogenes that promotes cell survival. The two antiapoptotic proteins 
modulate cell death primarily by affecting the mitochondrial sequestration of 
cytochrome c and several other proteins (Tudor et al., 2000). By this, the formation 
of apoptosome and the subsequent activation of caspases are directly affected. 
Expression of Bcl-2 proteins also stabilizes the mitochondrial transmembrane 
potential by regulating the proton flux, inhibits generation of reactive oxygen species 
(ROS), and prevents cytoplasmic acidification (Schendel et al., 1998). 
The Bax subfamily includes the proapoptotic proteins Bax and Bak which act as 
accelerators of apoptosis. In cells, Bax and Bak change conformation near the time of 
commitment to cell death and synchronize with the release of cytochrome c. This 
conformational change of Bax/Bak plays an essential role in the perforation of 
mitochondrial outer membrane (Antignani and Youle, 2006). Consequently, ion 
fluxes and consecutive loss of the mitochondrial membrane potential occur. 
As the name suggested, the BH3-only proteins carry only one BH3 domain. The 
well-studied members of this subfamily include Bad and Bid. Proapoptotic Bad 
protein interacts via its BH3 domain with Bcl-2 and BC1-XL to facilitate the actions of 
apoptotic stimuli (Tudor et al, 2000). Another BH-3 only protein Bid plays a role in 
linking the death-receptor signaling to the mitochondrial pathway. During the 
death-receptor mediated apoptosis, Bid is proteolytically cleaved by caspase-8 to a 
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pro-apoptotic form, the truncated Bid (tBid), from the inactive, intact Bid. tBid 
appears to interact physically with Bax to mediate a conformational change in the 
Bax N-terminus (Danial and Korsmeyer, 2004). This event triggers insertion of 
cytosolic Bax into the outer mitochondrial membrane and thus disrupts the 
mitochondrial integrity (Eskes et al., 2000). 
ii. Reactive oxygen species (ROS) 
ROS has been recently identified to play a regulatory role in apoptosis (Ott et 
al., 2007). ROS in fact refers to small and highly reactive molecules with unpaired 
valence shell electrons. ROS includes oxygen ions, free radicals and peroxides (Sen, 
2003).It is formed as a natural by-product of the normal metabolism of oxygen, 
mitochondria, the power house of the cell, would therefore be the primary site of 
production of ROS by oxidative phosphorylation (Storz, 2007). 
The overall system of oxidative phosphorylation includes five large 
multienzyme complexes, designated as complexes I，II, III, IV and ATP 
synthase .There are two main sites of superoxide generation in this system: NADH 
dehydrogenase at complex I，and the interface between CoQ and complex III at the 
inner membrane of mitochondria (Nishikawa et al., 2007). Once the superoxide is 
formed, it will rapidly discharge through the mitochondrial matrix to the cytosol 
where it changes to hydrogen peroxide (H2O2). Under normal circumstances, the 
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cellular antioxidant defence; system functions to eradicate the excess ROS produced. 
Manganese superoxide dismutase (MnSOD) detoxifies cells from superoxide 
released into the mitochondrial matrix, and the copper/zinc superoxide dismutase 
(Cu/ZnSOD) from cytosolic superoxide (Crompton, 1999). Moreover, water- and 
lipid- soluble vitamins are also powerful antioxidant to serve the purpose. 
Mitochondria itself can also contribute to the antioxidant defence by the oxidation of 
succinate (Orrenius et al., 2007). 
Physiological problems arise only when the damaging ROS cannot be 
eradicated by the innate antioxidative mechanisms, which leads to oxidative stress to 
the cells (Liu et al., 2002). Being such a reactive molecule present in the cells, the 
accumulation of ROS exerts devastating effects on the cells. Besides oxidizing the 
polyunsaturated fatty acids in phospholipids on membranous structure 
(Hernandez-Hernandez, 2005), damaging genomic DNA (Tsuzuki et al.’ 2007) and 
altering protein conformation (Sohal, 2002), ROS also disturbs the normality of 
mitochondria, leading to the onset of mitochondrial mediated apoptotic pathway. 
The first mitochondrial target of ROS is mitochondrial DNA (mtDNA). mtDNA 
is essential in encoding proteins and RNAs which are indispensable in regulating 
electron transfer and oxidative phosphorylation (Fleury et al., 2002). Due to the close 
proximity between the site of ROS production and mtDNA, the histone-free mtDNA 
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is more susceptible to ROS damage, which directly leads to mitochondrial 
dysfunction (Orrenius et al., 2007) 
The second target is the oxidation of mitochondrial proteins that are essential in 
the functions of electron transport chain. Superoxides are found to impose toxicity by 
direct oxidation and inactivation on iron-sulfur (Fe-S) proteins, such as aconitases, 
and therefore leading to the release of iron (Fridovich, 1997). The simultaneous 
release of Fe + ions after oxidation of aconitases is accompanied by the release of 
H2O2, which pose further oxidative burden to the cells (Liochev and Fridovich, 1999). 
Besides, oxidation of the enzyme also generates the potent hydroxyl radical, which 
can oxidize mitochondrial proteins, DNA, and lipids, thereby exacerbating the 
overall oxidative damage. 
The mitochondrial lipid peroxidation is the third target of ROS. Lipid peroxides 
alter vital mitochondrial functions, such as respiration and oxidative phosphorylation, 
inner membrane barrier properties, maintenance of mitochondrial membrane 
potential ( A a n d mitochondrial Ca buffering capacity (Cejas et al., 2004; 
Venditti et al., 2004), which all leads to the impairment of mitochondrial functions. 
In the mediation of mitochondrial apoptotic pathway, the release of cytochrome 
c is undoubtedly crucial (Slee et al., 1999). This event is mediated by ROS by the 
peroxidation of cardiolipin (Ott et al., 2007). Cardiolipin is one of the major 
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components of phospholipids which, in the mitochondrial membranes, functions to 
stabilized cytochrome c and other electron transport chain-related proteins present in 
the intermembrane space (Tuominen et al.，2002) and confers fluidity and mobility of 
the mitochondrial membrane (Ott et al., 2007). It is found that cardiolipin oxidation 
decreases its binding affinity for cytochrome c and facilitates cytochrome c 
mobilization from the intermembrane space (Ott et al., 2002), which is mediated by 
intracellular ROS accumulations. 
The role of ROS in the induction of apoptosis, particularly the mitochondrial 
mediated pathway, has been postulated and supported by numerous scientific 
evidences. Being highly toxic molecules, ROS mediates cell death pathway via a 
variety of cell death paradigms that wait to be fully elucidated. Mitochondrion, as a 
primary source of cellular ROS and a site of damages, is therefore tightly regulated 
by ROS on apoptosis induction. 
1.4 Phytochemicals from Traditional Chinese Medicine (TCM) as a source 
of new therapeutics 
Conventional therapeutic and surgical approaches have not been able to control 
the incidence of most of the cancer types. Despite the continuous efforts made on 
new anticancer drug discoveries, some of the cancers remain poorly treated. The 
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obstacles faced by the treating of cancers attributes to the occurrence of multidurg 
resistance (Gottesman et ^/.,2002), the metastatic properties of cancer cells (Aziz et 
al., 2003; Eccles and Welch, 2007) and the cytotoxicity of anticancer drug (de Bono 
et al. 2003 ； Crighton and Ryan, 2004) which limits the drug dosage to a tolerable yet 
effective level. Moreover, the heterogeneity of cancer cells and the complex signal 
transduction pathways behind nullify the efficacy of single, conventional 
chemotherapy. Thus, there is an urgent need to develop novel agents that provide 
promising therapies for the management of cancer. 
Natural organisms have evolved complex chemical defence and signaling 
systems that are designed for protection purpose and provide other biological 
benefits. These organisms thus produce substances containing novel chemotypes that 
may have beneficial effects for humans. In fact, over half of the current anticancer 
agents in clinical use are natural products or are derived from natural products 
(Cragg et al., 2005). Among the anticancer drugs approved by the United States Food 
and Drug Administration since 1960, over 50% of them were originated from the 
natural resources, especially from terrestrial plants (Kim and Park, 2002). Important 
anticancer agents such as paclitaxel and camptothecin are the renowned examples of 
plant-derived chemotherapeutic drugs, which are both discovered from terrestrial 
plants Taxus brevifolia and Camptotheca acuminata respectively (Brana and 
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Sanchez-Migallon, 2006).. Besides the discovery of therapeutics, plant-derived 
chemicals also serve as chemopreventive agents in cancer prevention. An increasing 
number of evidence has suggested that many dietary phytochemicals are efficacious 
in halting or reversing the perpetuation of carcinogenesis at different stages (Surh, 
2004). In this context, it can be appreciated that chemicals extracted from plants are 
particularly important, both as a potential therapeutics and as a chemopreventive 
agent (Liu et al., 2004). 
In the search of novels phytochemicals with potential anti-neoplastic effects, 
Traditional Chinese Medicine (TCM) would represent a rich and attractive pool of 
bioactive chemicals that deserves further investigation (Chen et al., 2006). Because 
of the growing interest in TCM-based therapeutic agents, increasing effort has been 
directed towards scientific proof, clinical evaluation and molecular analysis of 
components in the herbal medicine (Chen et al., 2003; Cohen et al., 2002). One of 
the scientifically well-established TCM candidates would be the medicinal fungus 
‘Ling Zhi', Ganoderma Lucidum. It has long been used as a folk remedy for 
promotion of health and longevity (Lin and Zhang, 2004), and the dried powder of 
Ganoderma lucidum was popular as a cancer chemotherapy agent in ancient China 
(Sliva, 2003). The immunomodulatory and anti-tumor activities of the fungus have 
been extensively studied, revealing the possible mechanisms by modulating 
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functions of immune cells. The polysaccharide and triterpene fractions of G. Lucidum 
exhibited significant anti-tumor effect in several tumor-bearing animals mainly 
through its immunoenhancing activity (Lin et al., 2003; Gao et al, 2005). Supporting 
by large amount of scientific evidence, the use of Ganoderma has been enforced in 
preclinical studies, which the combinatory use of G. Lucidum with 
hypercholesterolemia drug lovastatin have demonstrated promising effect on tumor 
regression (Shiao, 2003). The successful scientific profiling of this medicinal fungus 
and the identification of the bioactive components within have illustrated the 
potential of TCM in the development of novel anticancer regimens that deserves 
attention. 
1.5 Biological effects of baicalein 
Baicalein (5,6,7-trihydroxyl-2-phenyl-chromen-4-one) is a flavone extracted 
from the dried root of a Chinese medicinal plant called Scutellaria baicaleinsis 
(Huang Qin). Huang Qin is one of the important medicinal herbs widely used for the 
treatment of various diseases. Based on the theory of TCM, this drug is considered to 
be a detoxification and damp-removing agent and unblocks the lung and stomach 
meridians (Ye et al” 2002). In scientific language, this herbal medicine was 
traditionally used as an anti-inflammatory agent, which is effective in treating 
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inflammation-related illnesses such as respiratory tract infection, diarrhoea, jaundice 
and hepatitis (Zhang et al,, 2003). Besides, Huang Qin has also been used as a 
traditional antitumor herb. The anticancer activity possessed by the herbal medicine 
has been investigated, either alone or in combination with other herbs. Its antitumor 
activities has been verified in different types of cancers, including breast, 
hepatocellular, pancreatic, prostate, and urothelial carcinoma cell lines (Yano et al., 
1994; So et a/., 1997). Being an effective anti-tumor herb, Huang Qin is therefore one 
of the ingredients of the herbal formulation PC-SPES, which is a mixture of several 
Chinese herbs and one American herb Serenoa rep ens. PC-SPES is in fact a popular 
herbal supplement consumed by patients diagnosed with prostate cancer in the US 
(Hsieh et al, 2002) 
From the medicinal plant Scutellaria baicaleinsis, three major bioactive 
phenolic compounds have been identified, namely wogonin, baicalein and baicalin 
(Chen et al., 2001). Among the three bioactive flavanoids, baicalein has shown the 
strongest antiproliferative effects in several types of cancer in vitro (Chang et al., 
2002; Ma et al, 2005). 
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Fig. 1.2 Chemical structure of baicalein 
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1.5.1. Role of baicalein as a lipoxygenase inhibitor 
One of the possible mechanisms behind the antiproliferative effects of baicalein 
would probably be the inhibitory effect on lipoxygenases (LOXs). The function of 
LOXs is similar to the functions of cyclooxygenases (COXs) in the metabolism of 
polyunsaturated fatty acids, which both classes of enzymes oxidize the essential fatty 
acids such as arachidonic and linoleic acids to form a wide array of bioactive 
chemicals like prostaglandins and leukotrienes that are important in carcinogenesis, 
metastasis and angiogenesis (Kashfi and Ragas, 2005). Therefore, the COX and LOX 
pathways are often upregulated in cancer cells, and the use of COX and LOX 
inhibitors has been regarded as a possible direction in suppressing carcinogenesis and 
tumor progression (Ding et al., 2003). Baicalein is widely recognized as a potent 
inhibitor of the pro-carcinogenic 12-LOX which frequently employs in the study of 
lipoxygenase inhibition. The 12-LOX inhibition by baicalein has shown to attenuate 
the growth of prostate cancers (Ding et al” 1999) and gastric cancer (Wong et al, 
2001) in vitro and in vivo. 
1.5.2 Dual roles of baicalein as an antioxidant and prooxidant 
Similar to other bioactive flavonoids, baicalein possesses antioxidant and 
free-redical scavenging activities that are able to repress stress-induced cell death 
(Lin et al., 2007). Baicalein is able to induce the expression of stressed-induced 
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heme oxygenase 1 and the modulation of ERK signal transduction pathway, which is 
essential in inhibiting H202-induced apoptosis. The H202-induced apoptosis mimics 
the oxidative-stress-induced apoptosis that are commonly found after treatment of 
chemotoxic agent (Chen et al., 2006). As an antioxidant that can inhibit 
stress-induced cell death, baicalein also served as a potent free-radical scavenger by 
the suppression of xanthine oxidase activity (Shieh et al., 2000). 
Interestingly, besides acting as an antioxidant, baicalein is also capable in 
apoptosis induction via the upregulation of intracellular ROS production. Baicalein 
has been reported to induce ROS-mediated mitochondrial dysfunction in human 
promyeolytic leukemia by two different groups (Wang et al., 2004; Makino et al, 
2006). The criteria behind the switch of the dual roles played by baicalein are not yet 
elucidated. 
1.5.3 Roles of baicalein as an anti-carcinogenic, anti-proliferative and 
anti-metastatic agent 
Baicalein is able to exert its anticancer effect on the initiation phase of 
cancerous lesions. This is achieved by the modulation of enzyme activities resulting 
in the decreased carcinogenicity of xenobiotics. Baicalein is capable in activating the 
phase II detoxifying enzymes, which are essential in the detoxification of carcinogen. 
Being a bioactive flavone, baicalein also regulates the activity of aromatase (CYP19), 
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thus decreasing estrogen biosynthesis and producing antiestrogenic effects, which are 
important in the tumorigenesis and progression of breast and prostate cancers (Moon 
et al., 2006). Moreover, the administration of baicalein is capable in inhibiting cell 
shedding from primary tumor as well as the subsequent invasion at secondary site, 
supporting by the study using confrontation culture model consisting of multicellular 
tumor spheroids and embryoid bodies (Glinther et al., 2007). In the context of 
vascular network development in cancer cells, baicalein is able to inhibit 
angiogenesis in prostate cancer cells, which is probably due to its inhibitory effect of 
12-LOX that in turn reduces the expression of vascular epidermal growth factor 
(VEGF) in cancer cells (Nie et al., 2006) 
1.6 Aims of current study 
The demands for the discovery of new anticancer drugs have never been 
slowed down, despite the continuous efforts made on new drug development. The 
complexity of cancers and the practical difficulties in anticancer strategies have left 
many of the cancers poorly treated. Over 50% of the currently used anticancer drugs 
are originated from natural sources, particularly the terrestrial plants (Kim and Park, 
2002). This suggests the great potentials of further discovery of new therapeutics 
from the plant kingdom. In this context, TCM would represent a rich and attractive 
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pool of bioactive chemicals that deserved further investigation (Chen et al, 2006). 
Many studies have identified the bioactive compounds in some renowned TCM and 
have been enacted as complementary therapy. In this study, the antiproliferative 
effects of the TCM-derived flavone, baicalein, is investigated. Despite the previous 
researches on the antiproliferative mechanisms of baicalein in other types of cancer 
cells, the antiproliferative effects of baicalein on human melanoma A375 cells have 
never been reported by other researchers. Moreover, the various modes of actions 
demonstrated by baicalein on cancer cell growth inhibition previously have indicated 
the potentials of the discovery of new antiproliferative mechanisms. 
The application of analytical techniques, such as flow cytometry and 
immunoblotting, in the study of cell proliferation, apoptosis, and their regulatory 
gene expression are the mode of choice to provide new and important information on 
how baicalein exerts its in vitro anticancer activities on the melanoma cells. Findings 
from the experimental results are of crucial importance on the deduction of novel 
signal transduction pathways. We anticipate that the results from this study would 
allow more understandings on the anticancer mechanisms of baicalein on the 
melanoma cell line, the results of which may open a new direction in the research in 
melanoma treatment. As baicalein is derived from an inexpensive herb Huang Qin 
which is easily available, it merits in further research and development as a potent 
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cancer adjuvant therapeutic? agent. 
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Chapter 2. Effect of Baicalein on Growth and Survival of 
Human Cancer Cells 
2.1 Introduction 
In the evaluation on the cytotoxic effects of a potential compound, in vitro 
antiproliferative study has provided us with fast and inexpensive cytotoxic testings. 
Different assays for quantifying cell population have been established to assess the 
cell viability and proliferation of the drugs on cancer cells, based on different 
features of viable and non-viable cells. Among these parameters, the most prominent 
parameter associated with cell viability and proliferation would be the change in 
metabolic activity. Cellular damages will inevitably result in a loss of ability of the 
cell to maintain and provide energy for metabolic functions and growth, therefore 
based on this premise, metabolic activity can be assayed as a reflection of cell 
viability. 
In 1983, Mosmann described a rapid colorimetric assay for the measurements of 
cell growth and metabolic activity, which was called MTT assay (Mosmann, 1983). 
This assay, which is usually applied for adhesive cell line, is based on the reduction 
of the yellow water-soluble substrate 3-(4,5,-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) into a water insoluble dark blue formazan product by 
active mitochondrial dehydrogenases in living cells. As yellow water soluble MTT is 
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only reduced by active dehydrogenases in the functional mitochondria, the amount of 
formazan produced is therefore directly proportional to the viable cell number, and 
the result is found to be reliable over a wide range of drug concentrations (Page, 
2004). 
The degree to which anticancer agents selectively target cancer cells is a key 
determinant in successful therapeutic outcomes (Durvvri, 2006). A potential 
efficacious compound should also possess specificity in actions that preferentially 
targeted to cancer cells. Having indefinite proliferative and metastatic ability, 
cancerous cells present very different genotypic and phenotypic characteristics when 
compared with the controlled, normal counterparts. It is the differences that keep the 
two types of cells apart and provide therapeutic targets in combating cancer. 
Therefore as an attractive potential antitumor compound, it should display 
differential activities on cancer cells and normal cells, which only the cancer cells are 
being suppressed, leaving the normal, health cells slightly or even not affected. 
In the present study, MTT assay was applied for the preliminary screening of the 
growth inhibitory effect of baicalein on different cancer cells and a normal skin 
fibroblast cell line. The concentration of baicalein with 50 % inhibition on cell 
proliferation was also estimated for the comparison of growth inhibitory effects as 
well as for further investigation of the mechanistic actions accounting for its growth 
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inhibitory effects on the cancer cells. 
2.2 Materials and Methods 
2.2.1 Cell culture 
Six human cancer cell lines including malignant melanoma A375, colorectal 
carcinoma Caco-2, hepatocellular carcinoma HepG2, lung carcinoma A549, prostate 
carcinoma PC-3 and breast carcinoma MCF7 cells; and one human skin fibroblast 
cell line Hs68 were used to study the cytotoxic and cytostatic effects of baicalein in 
this study. All cell lines were provided by American Type Culture Collection (ATCC; 
Rockville, MD). All media used, unless otherwise stated, were purchased from Gibco 
(Rockville, MD). A375, Caco-2 and Hs68 cells were grown in Dulbecco's Modified 
Eagle Medium (DMEM). A549 and PC-3 cells were grown in F12K medium (Sigma, 
St. Louis, MO) while Hep-G2 and MCF7 cells were grown RPMI-1640 medium and 
Eagle's Minimum Essential Medium (EMEM), respectively. All media were 
supplemented with 0.2 % sodium bicarbonate (Sigma), 10 % heat-inactivated fetal 
bovine serum, 100 U/ml penicillin and 100 jig/ml of streptomycin (all from Gibco). 
In addition to the above supplements, the growth medium for MCF7 cells was further 
supplemented by 1 mM sodium pyruvate and 0.01 mg/ml bovine insulin (both from 
Sigma). The cells were maintained under a fully humidified atmosphere with 5 % 
CO2 at 37 °C, and passaged three times a week.. 
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2.2.2 Measurement of growth and survival of various cell lines 
MTT assay was applied to examine the effects of baicalein on cell growth 
control. Different cancer cells and the normal skin fibroblast cell line were seeded in 
96-well flat-bottomed culture plates at an initial number of 5 x 103 cells and 1 x io4 
cells per 100 jal respectively. The cells were acclimatized for 24 h before incubation 
with 0 - 100 |iM of baicalein (Sigma) for 48 h. After incubation, 20 jul of the MTT 
solution was added to each well and further incubated for 5 h. The MTT solution was 
freshly prepared by dissolving MTT (Sigma) in filtered phosphate-buffered saline 
(PBS) at 5 mg/ml. After 5 h of incubation, the wells were carefully aspirated and the 
blue formazan formed was dissolved by adding 150 |il dimethyl sulphoxide (DMSO). 
All the wells were then mixed by pipetting until all crystals were dissolved 
completely. Absorbance of the blue formazan solution generated was measured at 
570 nm by the microplate reader. The inhibitory effects of baicalein on the tested cell 
lines were expressed as percentage inhibition, which was calculated by the following 
equation: 
Average absorbance of treatment group 
1 - x 100% 
� Average absorbance of control group � 
The percentage inhibition calculated was plotted against the corresponding 
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concentration of baicalein tested. The concentration of baicalein with 50 % inhibition 
on the growth and survival (i.e. IC50) on each cell line was then estimated from the 
growth-inhibitory plot. 
2.2.3 Statistical analysis 
Results were expressed as mean 土 standard deviation (S.D.) and analyzed by 
Student's ^-test. The level of significance was taken at p=0.05, p=0.01 and p=0.001. 
2.3 Results 
2.3.1 Baicalein retards the growth and survival of human melanoma A375 
and colorectal carcinoma Caco-2 
Effects of baicalein on the growth and survival of a panel of human cancer cells 
of different histotypes were studied with MTT assay. Among the six cancer cell lines 
tested, baicalein only reduced the growth and survival of human melanoma A375 and 
colorectal carcinoma Caco-2 in a dose-dependent manner, while no significant 
growth inhibition was observed in the other four cell lines, namely hepatocellular 
carcinoma Hep-G2, lung carcinoma A549, prostate carcinoma PC-3 and breast 
carcinoma M C F 7 cells. At the highest concentration of 100 JIM after 48 h of 
incubation, baicalein reduced the growth and survival of A375 and Caco-2 cells by 
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76.0 % and 67.3 % respectively, when compared to their control levels (Fig. 2.1). 
The values of IC50 of baicalein on A375 and Caco-2 were then estimated as 37.5 and 
84.0 jj,M, respectively. Since melanoma A375 was found to be the most responsive 
cell line to the inhibitory effect of baicalein, further studies were performed on this 
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Fig. 2 .1 Effects of baicalein on growth and survival of various human 
cancer cell lines 
The growth and metabolic activities of A375，Caco-2, Hep-G2, A549, 
PC-3 and MCF7 were measured by MTT assay after incubation with 0-
100 |iM of baicalein for 48 h. Baicalein only reduced the growth and 
survival of A375 and Caco-2 cells but not the other cancer cell lines. 
Results are expressed as mean 士 S.D. (n=4). ** p<0.0\, compared to 
the control level by Student's 广-test. 
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2.3.2 Baicalein reduces the growth and survival of melanoma A375 but not 
in normal skin fibroblast Hs68 cells 
As mentioned in section 2.3.1, baicalein significantly reduced the growth and 
survival of melanoma A375 cells. In this study, the inhibitory effect of baicalein on 
the normal skin fibroblast Hs68 cells was investigated. Interestingly, as illustrated by 
MTT assay, lower dose of baicalein, i.e. 6.25-50 \iM, were stimulatory instead of 
inhibitory on the growth and survival of the skin fibroblast after 48h of incubation 
(Fig. 2.2). Although IOOJIM baicalein seemed to reduce the growth and survival of 
the normal cells by 11.8% of the control level, the inhibition was not statistically 
significant. At the same concentration, baicalein was able to reduce the growth and 
survival of the melanoma cells by 76%, indicating that the inhibitory effect of 
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Fig. 2.2 Effects of baicalein on growth and survival of human melanoma 
A375 and human skin fibroblast Hs68 cells 
The growth and metabolic activities of the melanoma and the skin 
fibroblast were measured by MTT assay after incubation with 0-100 
JLIM of baicalein for 48 h. Results are expressed as mean 士 S.D. (n=4) 
** and *** represent statistical significance levels at/><0.05,p<0.01 





Being a rapid, economical and simple assay (Page, 2004)，MTT assay was 
employed to study the inhibitory effects of baicalein on a panel of cancer cell lines of 
different histotypes in vitro. Human melanoma A375，colorectal carcinoma Caco-2, 
hepatocellular carcinoma HepG2, lung carcinoma A549, prostate carcinoma PC-3 
and breast carcinoma MCF7 cells were included in the testing panel. The results from 
MTT assay were illustrated in a growth-inhibitory plot, where the IC50, i.e., the 
concentration of compound that causes 50% of cell growth reduction compared to 
the control level, of baicalein was estimated. The lower the value of IC50, the more 
efficacious the bioactive compound would be against the cell growth reduction 
(Budman et al., 2003). Baicalein exhibited differential effects on different cell lines. 
Only human melanoma A3 7 5 and colorectal carcinoma Caco-2 showed significant 
growth inhibition after baicalein treatment, with the value of IC50 of 37.5 and 84.0 
jiM, respectively (Fig 2.1). Meanwhile, hepatocellular carcinoma HepG2, lung 
carcinoma A549, prostate carcinoma PC-3 and breast carcinoma MCF7 did not 
respond prominently to baicalein treatment even at maximum dose of 100 |LIM. 
Consequently, human melanoma A375, being the most responsive cancer cell line, 
was chosen for further studies. 
Before moving on to investigate the inhibitory mechanism of baicalein for A375 
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cells, the specificity of baicalein on cancer cells was investigated by comparing its 
effect on the melanoma cell line with that on a normal human skin fibroblast cell line 
Hs68 (Fig. 2.2). This normal cell line had also been previously employed to evidence 
the specific antiproliferative effect of bioactive chemicals on hepatoma cells (Chan et 
al., 2004). Interestingly, instead of inhibiting cell growth and survival, baicalein 
stimulated the growth of the fibroblast cell line. All these results substantiate that 
baicalein is generally non-toxic and possesses specific growth-inhibitory effect on 
the melanoma cells. 
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Chapter 3. Effects of Baicalein on Cell Cycle and the Apoptosis 
in Human Melanoma A375 Cells 
3.1 Introduction 
Ultimately, cancer is the consequence of the loss of balance between cell 
proliferation and cell death (Thompson, 1995). Baicalein has been shown to retard 
both cell proliferation and viability of the human malignant melanoma A375 cells 
(Chapter 2.1); however, the underlying mechanisms remain unclear, thus different 
aspects of its cell growth inhibitory activity were further explored in this study. 
The proliferation of eukaryotic cells is governed by series of events comprised 
the cell cycle. Any factors that affect the genes and/or proteins regulating the 
cell-cycle progression will cause a delay or an arrest of the cell-cycle phase, leading 
to delayed proliferation. Cell cycle analysis therefore provides a useful tool to 
evaluate the effects of exogenous compounds on cell proliferation. Thus, how 
different lengths of baicalein treatment affect the cell cycle profile of the melanoma 
cells, in terms of cell cycle distribution, was evaluated by the application of flow 
cytometry. Furthermore, as baicalein inhibited the growth of the melanoma, the 
inhibitory effect might probably due to the perturbing of cell cycle progression, and 
the subsequent induction of cell death. The induction of cell death by baicalein could 
also be visualized in the DNA flow cytometric analysis concerning the characteristics 
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of apoptosis, DNA fragmentation (Bedner, 1999). By the appearance of the apoptotic 
peak on the DNA histogram, the modes of cell death triggered by baicalein could be 
distinguished. During apoptosis, chromosomal DNA will be fragmented into 
specifically 50- to 200-kb fragments, then later into nucleosomal units of DNA 
fragments (Nagata, 2000). Therefore, cells undergoing apoptosis will appear as 
discrete peak (sub-Gi peak) on the left of Gi peak (Compton, 1992; McConkey et al., 
1996). Unlike apoptosis, necrosis does not trigger extensive DNA degradation 
comparable to that of apoptosis; also the products of degradation are heterogenous in 
size therefore fail to form discrete peaks on the DNA histogram (Darzynkiewicz et 
al., 1997). As a result, the observation of discrete sub-Gi peaks may serve as an 
evidence of the occurrence of apoptosis. 
DNA Flow Cytometric Analysis 
One of the important applications of DNA flow cytometry is to study the hypo-
and hyperdiploidy of cancer cells (Vermes et al., 2000), which is based on the 
measurement of fluorescent signals emitted by DNA-binding dye, such as propidium 
iodide (PI). PI is a fluorogenic DNA dye that intercalates within double-stranded 
DNA in a specific stoichiometric manner (i.e. the extent of staining is directly 
proportional to the amount of DNA within the cells) (Darzynkiewicz et al, 1992). 
After staining the fixed cells with PI, the red fluorescence from the dye can be 
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measured at 620 to 740 nm after excitation by laser beam at 488 nm by flow 
cytometer. A DNA histogram is thus generated to illustrate the DNA content of the 
entire cell population. 
DNA histogram is the frequency distribution generated from the relative PI 
fluorescence of thousands of individual cells detected by the photomultiplier tubes of 
flow cytometer. The x-axis represents the channel number. Fluorescence of the light 
pulse from each signal is digitalized and converted into a channel number. Therefore, 
the channel number thus reflects the relative amount of DNA in each nuclear unit. 
The y-axis refers to the number of counts per channel, which corresponds to the 
relative number of cells. The DNA histogram is constructed by plotting the relative 
number of cells against the increasing channel numbers, therefore representing the 
DNA content distribution of cells from the cell population (Rabinovitch, 1994). 
A typical DNA histogram is shown in Fig. 3.1 with the shape of two peaks 
separated by a trough. The first peak represents the G0/Gi phase, in this period; the 
DNA content is the least in the cell cycle which represents the DNA content of 
non-dividing cells. The second peak represents the G2/M phase in which the DNA 
content of the cells is duplicated and is ready to divide into respective daughter cells. 
In between these two peaks is the S phase in which DNA is actively synthesized, 
where the DNA content is increasing. In the case of apoptotic cells, a peak with 
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lower DNA content on the. left of Go/Gi peak will be detected, which is termed as 
apoptotic peak (Ap). During apoptosis, endonuclease(s) may be activated and results 
in the DNA fragmentation at internucleosomal regions generating nucleosomal and 
oligonucleosomal DNA (Nagata, 2000). These DNA fragments are extracted and the 
remaining DNA within the apoptotic cells becomes lower in content than those of Gi. 
The red fluorescence intensity from the apoptotic cells is thus lower, and exists as the 
apoptotic peak on the left of Gi peak in DNA histogram. 
DNA histogram analysis allows an objective approximation for the population 
of cells in the G0/Gi, S an G2/M phases of cell cycle which acts as a crude index of 
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Fig. 3.1 A DNA histogram of flow cytometry 
A eukaryotic cell cycle is divided into G0/Gi, S and G2/M phases. An 
apoptotic peak (Ap) is also found on the left of the G0/Gi peak. 
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Besides the physical characteristics, biochemical characteristics of apoptosis are 
also prominent indicators readily available for the detection of apoptosis. Caspase 
activation is one of the important biochemical features commonly found in apoptotic 
cells. Being able to self-activated or activated by other caspases, caspases are 
responsible for the initiation, execution and amplification of the apoptotic cascade 
(Kumar, 2007). Therefore the detection of activated caspase is a convincing piece of 
evidence supporting the occurrence of apoptosis. One of the duties of active caspase 
is the demolition of unwanted cellular materials, which include the proteolytic 
inactivation of poly(ADP-ribose) polymerase (PARP). PARP is an enzyme that 
governs the process of poly(ADP-ribosylation), which is a post-translational 
modification of proteins that, in eukaryotic cells, plays a crucial role in DNA repair 
and replication, transcription and cell death, and represents a cellular emergency 
reaction (Scovassi and Poirier, 1999). In the late phase of apoptosis, PARP is 
inactivated by caspases in order to halt the DNA repair machinery and to signal the 
cells to massive apoptosis. To verify and confirm if the baicalein-induced apoptosis 
is a caspase-dependent event, protein expression of various caspases and PARP was 
investigated by immunoblotting and the application of specific caspase inhibitor in 




Immunoblotting, also known as Western blotting, is an analytical method 
commonly employed in the analysis of protein expression of cells. It comprises 
basically two steps: sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) and immunoblotting of the fractionated proteins from the gel to 
nitrocellulose membrane. 
Electrophoresis is a widely used and powerful technique to fractionate proteins, 
which depends on the ability of charged molecules to migrate when placed in an 
electric field. The separation of proteins is usually accomplished using 
polyacrylamide gel electrophoresis (PAGE) in which the electrophoretic move of 
proteins is carried out through a gelated matrix, polyacrylamde, which is the polymer 
of acrylamide that are cross-linked to form a molecular sieve. The larger the protein, 
the more it becomes entangled, and the slower it migrates. PAGE is usually carried 
out in the presence of the negatively charged detergent sodium dodecyl sulfate (SDS). 
The electrostatic repulsion between the bound SDS molecules causes the proteins to 
unfold into similar rodlike shape, thus eliminating differences in shape as a factor in 
separation. Furthermore, the negatively changed SDS molecules bind to protein 
molecules stochiometrically which mask the intrinsic charges of proteins. 
Consequently, each protein species, regardless of its size, has an equivalent charge 
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density and is driven through the gel with the same force. As a result, proteins 
become separated by SDS-PAGE on the basis of a single property, which is the 
molecular mass (Lodish et al., 2000). 
3.2 Materials and Methods 
3.2.1 Determination of cell cycle changes and quantitication of apoptosis 
To determine the cell cycle changes after baicalein treatment, the melanoma 
cells were seeded at an initial density so that at the end of treatment 1x10 cells were 
harvested. After 24 h acclimatization, the cells were treated with or without 37.5 |iM 
baicalein for 24, 36 48, 60 and 72 h. After treatment, the cells were harvested and 
washed with PBS and fixed in 70% ethanol at -20 0C for 24 h. The cells were then 
incubated in dark for 30 min with 1 mg/mL ribonuclease A (RNase A; Sigma) and 10 
(ag/mL propidium iodide (PI; Sigma) in PBS. The DNA content in the stained cells 
was thus analyzed by measuring PI fluorescence using the Epics XL-MCL flow 
cytometer (Beckman Coulter, Miami, FL) at excitation wavelength > 625 nm. 
Different populations of cells exhibiting different DNA content were interpreted as 
cells in different phases of cell cycle. Simultaneously, cells with hypodiploid DNA 




a. Protein extraction 
Preparing whole cell lysates，cells were harvested and homogenized for 30 
minutes on ice in a protein lysis buffer (20 mM Tris-HCl at pH 8.0, 150 mM NaCl，5 
mM EDTA，0.2% BSA，1% Triton X-100) supplemented with protease inhibitors 
(BD Biosciences, San Jose, CA). Organelles and cell debris in the cell lysates were 
precipitated and removed by centrifiigation at 4 °C for 15 minutes at 15 OOOg. The 
resulting supernatants were frozen at -20 °C or used immediately. Aliquots of the 
supernatants were used for protein concentration determination by the standard 
bicinchoninic acid (BCA) assay kit (Pierce, Rockford, IL). 
b. Determination of protein concentration 
After cell lysates preparation, the protein concentration of the lysate was 
determined by BCA assay kit (Pierce, Rockford, IL). Briefly, standard curve was first 
prepared with 0，25, 50, 100, 200 and 400 jug/ml of bovine serum albumin (BSA) per 
50 \i\ in microcentrifuge tubes for calibration. Meanwhile, 1 \x\ of total cell lysates 
was diluted with 49 |il ultrapure water for protein content measurement. 1 ml of 
freshly-prepared BCA assay solution was added to each microcentrifuge tube before 
incubation at 37 °C for 30 min. After the incubation, the tubes were cooled to room 
temperature and the absorbance was measured at 562 nm by spectrophotometer 
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(Eppendorf, Hamburg, Germany). A calibration curve was constructed with the 
absorbance of the standards and the protein concentration of the sample cell lysate 
was therefore estimated. 
c. Sodium Dodecyl Sulphate-Polyarcylamide Gel Electrophoresis (SDS-PAGE) 
Samples (30 — 80 jig protein) were denatured in Laemmli loading dye at 95°C 
before resolving on 8 or 13% polyacrylamide gel. Resolved proteins on the gels 
were then transferred onto nitrocellulose membranes (Hybond ECL; Amersham, 
Buckinghamshire, UK) under an electric field of 105 V for 1 h. 
d. Immunodetection 
The membranes adhered with proteins were then blocked for 1 h in 
Tris-buffered saline (TBS) with 0.1% Tween-20 containing 5% non-fat dry milk. 
Immunodetection of was performed by overnight incubation at 4 °C with primary 
antibodies diluted in the same blocking buffer. In this experiment, primary 
antibodies against PARP, caspase-8, caspase-3, caspase-9, and Bid (Cell Signalling 
Technology, Beverly, MA) were used under dilution factor of 1:1000 and antibody 
against (3-actin (Sigma) were used under dilution factor of 1:5000. The blots were 
then probed with horseradish peroxidase (HRP)-conjugated secondary antibodies 
(Cell Signalling Technology) for 1 hour at room temperature at a dilution of 1:2000, 
and proteins were visualized by enhanced chemiluminescence (Cell Signalling 
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Technology) and captured by X-ray films. 
3.2.3 Inhibition of caspase-8 by caspase-8 inhibitor 
The consequences after inhibition of caspase-8 in A375 cells was studied by the 
administration of caspase-8 inhibitor (Z-IE(OMe)TD(OMe)-FMK) (Calbiochem). 
Firstly，1 x 106 cells were acclimatized for 24 h before baicalein treatment. The cells 
were then pre-treated with 40 |iM caspase-8 inhibitor for 1 h. After pre-incubation, 
baicalein at IC50 was added to further incubate for 48 h. The cells were then 
harvested for immunoblotting (section 3.2.2) and for caspase-3 activity assay 
(section 3.2.4) 
3.2.4 Fluorometric measurement of caspase-3 activity 
Caspase-3 activity was determined using Caspase-3 activity Kit (BD 
Biosciences). Briefly, cell lysates were prepared from 1 x 106 cells after incubation 
with baicalein at IC50 for 48 h. After thorough washing with PBS, cell pellet was 
resuspended in cold cell lysis buffer (provided) and incubated for 30 min on ice. 
Subsequently, 25 jil cell lysate and 5 jxl fluorogenic caspase-3 substrates 
(Ac-DEVD-AMC) were mixed in a HEPES reaction buffer (provided), and incubated 
for 1 hour at 37 °C. The amount of enzyme-catalyzed AMC release was measured by 
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a fluorescence plate reader (Tecan, Grodig, Austria) with an excitation wavelength of 
380 nm and an emission wavelength of 440 nm. Fluorescence values generated in 
each treatment was converted into fold changes of the control. 
3.2.5 Statistical analysis 
Results were expressed as mean 士 S.D. and the statistical significance of the 
difference between control and the treatment groups was determined by one-way 
ANOVA followed by Tukey's test for multiple comparisons. The level of significance 
was taken at p=0.05. 
3.3 Results 
3.3.1. Baicalein induces S-phase arrest in cell cycle and triggers apoptosis 
As mentioned in section 2.3.1, baicalein reduced the growth survival of A375 
by 50 % at 37.5 jiM after 48 h of incubation. In this study, by using DNA flow 
cytometry, cells in different cell-cycle phases were measured in the melanoma cells 
and thus the regulation of baicalein on cell cycle progression was elucidated. The 
cancer cells were treated without, i.e., control, or with 37.5 \xM of baicalein, i.e., IC50, 
and incubated for 24 to 72 h. Baicalein induced time-dependent accumulation of 
S-phase cells and depletion of G0/1- phase cells, so that both the accumulation and the 
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depletion peaked at 60 h (Fig. 3.2). At 60 h of incubation with baicalein, the 
proportion of cells at S phase increased from the control 30.36 % to 50.93 %; the 
cells in G0/1 phase, in meanwhile, reduced from 53.57% to 33.07% (Fig. 3.3). 
Besides regulating the cell cycle, baicalein also induced apoptosis, in A375 cells. 
This was evidenced by the appearance of hypodiploid cells in the DNA histogram, 
indicating that cells were undergone DNA fragmentation, and lost their DNA content 
(Fig. 3.2). This population of cells, named as sub-Gi population, is a possible 
indicator of apoptosis. After the baicalein treatment, there was a time-dependent 
increase of sub-Gi population, i.e. the apoptotic population (Ap), concomitant with 
the time-dependent increase of S-phase and decrease of Go/i-phase cell population. 
The apoptotic population increased especially prominent from 36 h onwards, so that 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.3.2. Baicalein induces proteolytic inactivation of PARP and activation of 
caspases 
As hypodiploid cells with fragmented DNA were observed in the DNA 
histogram after flow cytometric analysis, effect of baicalein on the proteolytic 
inactivation of PARP was therefore investigated by immunoblotting to substantiate 
the occurrence of apoptosis. At 36 h incubation with baicalein, proteolytic 
inactivation of PARP was initiated in the melanoma cells, as the p89 cleaved PARP 
fragment was detected by immunoblotting. This indicated the incidence of apoptosis. 
From 36 h onwards, the cleavage was intensifying time-dependently so that at 60 h 
and 70 h, intact PARP was absent in the immunoblotting (Fig 3.4, the most upper 
panel). Therefore, both DNA flow cytometry and PARP immunoblotting showed that 
37.5 \iM baicalein induced time-dependent apoptosis in A375 cells starting from 36 h 
of incubation. 
Activation of caspases is another hallmark of apoptotic cell death. To investigate 
whether the baicalein-induced apoptosis is a caspase-dependent event, cell lysate was 
immunoblotted against specific antibodies for caspase-8, caspase-3 and caspase-9. 
After the baicalein treatment, the three studied caspases were activated sequentially. 
Caspase-8 possessed the proteolytic activation as early as 24 h of baicalein treatment 
as early as 24 h of baicalein treatment, which was evidenced by the presence of the 
active pi8 fragment. Thereafter, caspase-3 and caspase-9 were both activated at 48 h. 
This was indicated by the presence of the activated pi7 caspase-3 fragment, and the 
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activated p37 and p35 caspase-9 fragments from 48 h onwards (Fig 3.4，lower 
panels). 
Encapsulating the above findings, it was found that baicalein could induce 
caspase-dependent apoptosis, revealed by the inactivation of the genome guarding 





















































































































































































































































































































































































































































































































































































































































3.3.3. Caspase-8 is the major initiator caspase eliciting the baicalein-induced 
apoptosis 
In the previous section (section 3.3.2), it was found that baicalein could induce 
apoptotic cell death in A375 cells by sequential activation of caspases, in which 
caspase-8 was activated as early as 24 h of treatment. Since prominent apoptosis was 
only found at 36 h of baicalein incubation, it was hypothesized that caspase-8 would 
be the major initiator caspase responsible for the onset of baicalein-induced apoptotic 
cascade. To verify the hypothesis, 40 \iM caspase-8 inhibitor 
(Z-IE(OMe)TD(OMe)-FMK) was pre-treated with A375 cells 1 h prior to baicalein 
treatment. After further incubation with baicalein at IC50 for 48 h, expressions of 
PARP, and the two down-stream substrates of caspase-8, i.e. caspase-3 and Bid, were 
studied by immunoblotting. It was revealed that after caspase-8 inhibition, the level 
of PARP inactivation, indicated by the amount of p89 inactive fragment, was reduced 
and became comparable to the control level. (Fig 3.5). Besides, caspase 3 was also 
de-activated after co-incubation of caspase-8 inhibitor with baicalein, indicating a 
correlation between caspase-8 activity and caspase-3 activation. Bid, another 
substrate of caspase 8, did not show any significant change either after baicalein 
treatment or after capsase-8 inhibitor co-administration with baicalein. Since 
truncated Bid (tBid)，produced via cleavage of Bid by caspase 8, had been shown 
previously in activating the intrinsic apoptotic pathway, this implied that caspase-8 
activity did not take a major role in the proteolytic activation of caspase-9. The 
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Fig. 3.5 Representative immunoblots showing the effect of casapse-8 
inhibitor on baicalein-induced apoptosis 
The melanoma cells were incubated in the absence, i.e., control, or in 
different combinations of baicalein at IC50 and 40p,M caspase-8 
inhibitor (Z-IE(OMe)TD(OMe)-FMK) for 48 h. The caspase-8 
inhibitor retarded the baicalein-induced PARP and caspase-3 cleavage 
so that they became comparable to the control level. Neither baicalein 
treatment alone nor co-administration with caspase-8 inhibitor affected 
Bid expression. 
p-actin was also detected as internal control to normalize the 
expressions of other proteins. 
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To consolidate the findings that caspase-8 involves in the activation of 
caspase-3 and subsequently the induction of apoptosis, caspase-3 activity was 
measured after different combinations of baicalein and caspase-8 inhibitor treatment. 
Specific caspase-3 fluorogenic substrate, Ac-DEVD-AMC, was then added to the 
cells, and the activity of caspase-3 was measured according to the intensity of 
fluorescence of free AMC released by active caspase-3. After baicalein treatment 
alone, caspase-3 activity was significantly elevated to 3.6 fold of the control level, 
which was agreed with the immunoblotting result mentioned previously. After 1 h 
prior treatment with the caspase-8 inhibitor, the baicalein-induced caspase-3 activity 
diminished to only 2 fold of the control level. (Fig. 3.6) 
To sum up, caspase-8, the earliest caspase being activated by baicalein, plays an 
initiating role in the baicalein-induced, caspase-dependent apoptosis. This was 
evidenced by the reversal of PARP inactivation and de-activation of caspase-3 after 





































































































































































































































































































































































































































































































As mentioned in chapter 1, cellular homeostasis is maintained by the balance 
between cell proliferation and cell death. A network of overlapping molecular 
mechanisms is involved in the exquisite control of cell proliferation and programmed 
cell death, i.e. apoptosis. Any aberrant changes in either branches of the cellular 
homeostasis may result in increased cellular multiplicity, resulting in the formation 
of neoplasia that may become cancerous (Bertram, 2001). 
Uncontrolled cell proliferation is one of the profound characteristics that can be 
observed in cancer cells. Proto-cancer cells often acquired mutations that drive 
uncontrolled cell-cycle progression so that the mutated cells can escape from the 
homeostatic restraints and growth autonomously (Lowe et al., 2004). As a result, 
many anticancer drugs are developed aiming at the deregulated cell cycle in cancer 
cells (Donovan et al., 2005) In order to further assess the growth-inhibitory effect of 
baicalein on A3 7 5 cells, cell cycle after baicalein treatment was investigated, aiming 
at revealing capability of the phytochemical to halt the uncontrolled cell cycle 
progression and thus hinder cell growth. There are four serial biologically defined 
phases in cell cycle: Gi (first gap), S (DNA synthesis), G2 (second gap), and M 
(mitosis). Among and within different phases of the cell cycle, checkpoints are 
present to ensure proper completion of the steps in the previous phase prior 
proceeding to the next phase (Eastman, 2004). The change of cell cycle was studied 
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by DNA flow cytometry, and the cells at different phases of cell cycle were 
determined by their difference in DNA content. As shown in the DNA histograms, 
baicalein initiated a prominent S-phase arrest in the melanoma cells after 36 h of 
incubation. The S-phase arrest persisted and the cells were accumulating 
continuously up to 72 h of incubation. The baicalein-induced S-phase arrest was 
accompanied by the progressive decreases of G0/i cells. This further illustrated that 
the treated melanoma cells were able to pass through the Gi checkpoint prior to the 
DNA synthesis, but could not pass through the G2 checkpoint after doubling the 
DNA content and undergo mitotic division, i.e. entering the M phase of cell cycle. 
Similar S-phase arrest in A375 cells was also been reported after treatment with a 
catechin derivative (Lozano et al., 2005). 
Prolonged cell cycle arrest will initiate cells to undergo apoptosis, so that the 
hypodiploid cells may appear in DNA histogram because of DNA fragmentation, 
which is a characteristic feature of apoptosis (Fischer and Schulze-Osthoff, 2005). At 
the early stage of apoptosis, chromosomal DNA will be fragmented into 50- to 
200-kb fragments, then later into nucleosomal units of DNA fragments (Nagata, 
2000). Therefore, cells undergoing apoptosis will appear as discrete peak (sub-Gi 
peak) on the left of Gi peak, indicating the presence of hypodiploid nucleosomes in 
the DNA histogram (Compton, 1992; McConkey et al., 1996; Tanuma and Shiokawa, 
1996). The sub-Gi population apparently appeared after 36 h of baicalein incubation. 
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This apoptotic population was then increasing synchronously with the 
S-phase-arrested cells, so that more than 50% of the cells had undergone apoptosis at 
60 h of treatment. 
To further manifest the occurrence of apoptosis in baicalein-treated cells, 
proteolytic inactivation of PARP was studied by immunoblotting. PARP is an enzyme 
that governs the post-translational modification of proteins involved in DNA repair, 
cell death and cellular emergency reactions (D'Amours et al., 1999; Pieper et al., 
1999). This reaction, named as poly(ADP-ribosyl)lation, is important in maintaining 
genome integrity, particularly at times when DNA nicks were detected (Scovassi and 
Poirier, 1999). At the early stage of apoptosis, when DNA fragmentation begins, 
PARP activity is first stimulated for DNA repair; however, when a massive apoptotic 
DNA fragmentation occurred which signals a "no-return" cell death, PARP will be 
cleaved and become inactivated (Scovassi et al., 1998). Consequently, 
immunodetection of the cleaved products of PARP has been regarded as a prominent 
evidence of apoptotic cell death (Soldani et al., 2001). From the immunoblotting 
result, occurrence of apoptosis is evidenced by the presence of the cleaved p89 
fragment of PARP. The cleaved fragment started to appear after 36 h of treatment. 
The proteolytic inactivation was then intensified with prolonged baicalein incubation, 
as shown by the increasing intensity of the p89 fragment. Starting from 60 h and 
afterwards, massive apoptosis took place which signalled the subsequent degradation 
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of intact PARP so that no intact 116-kD PARP, but only the p89 proteolytic product 
was detected. 
After confirming the induction of apoptosis by baicalein, we were interested in 
the upstream signalling events that lead to it. Caspases have been regarded as the 
enzymes of apoptosis (Zonig et al” 2001; Crighton and Ryan, 2004). This family of 
intracellular proteases can either be self-activated or activated by other caspases 
before participating in the proteolytic cascade in apoptosis (Cryns and Yuan, 1998; 
Thornberry and Lazebnik, 1998). According to their functions in the apoptotic 
cascade, caspases can be divided into two subclasses: the initiator caspases, including 
caspase-8 and -9; and executioner caspases, including caspase-3, -6 and -7. Nearly all 
caspases have been reported previously to be able to proteolytically inactivate PARP 
in vitro (Soldani et al., 2001). Therefore, the activation of various caspases was 
studied by immunoblotting. Interestingly, we found that caspase-8, -3 and -9 were 
activated at different times of baicalein treatment. Caspase-8 was found to be the 
earliest caspase activated after 24 h of treatment, whereas both caspase-3 and -9 were 
activated after 48 h. This sequential activation suggested that the extrinsic apoptotic 
pathway, in which active caspase-8 is an initiator caspase of the pathway (Ghobrial et 
al., 2005)，was elicited after baicalein treatment. Involvement of the extrinsic 
pathway in the baicalein-induced apoptosis was further evidenced by the 
pharmacological inhibition of caspase-8 so that the activation of its downstream 
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substrate caspase-3 was terminated (Budihardjo et al., 1999). Cleavage of PARP was 
also rescued consequently. 
From these results, it is revealed that baicalein induces apoptosis in A375 cells 
first through S-phase cell cycle arrest prior to apoptosis. The apoptosis is 
caspase-dependent and the death receptor signalling pathway is elicited. 
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Chapter 4. Effects of Baicalein on the Extrinsic Apoptotic 
Pathways in Human Melanoma A375 Cells 
4.1 Introduction 
Besides acting as an evidence to support the elicitation of apoptosis, activation 
of different caspases also serves as an indicator which the apoptotic pathways 
involved can be identified. In the previous chapter, we have demonstrated that 
caspase-dependent apoptosis was elicited by baicalein in A375 cells. Among the 
caspases activated, caspase-8 was activated at the earliest time of treatment. 
Caspase-dependent apoptosis can be triggered via two pathways: the extrinsic 
death-receptor pathway and the intrinsic mitochondrial pathway. Caspases involved 
in apoptosis can basically divide into two subtypes: the initiator caspases (caspase-2, 
-8, -9 and -10)，which responsible to the detection of death signals prior to 
self-activation, and the effector caspases (caspase-3, -6 and -7) which are responsible 
for cell demise after activated by the initiator caspases. From the two subsets, 
caspase-9 is regarded as the leading caspase in the intrinsic mitochondrial pathway; 
whereas caspase-8 is the key initiator of death-receptor mediated apoptosis (Kumar, 
2007). The early activation of caspase-8 in baicalein-induced apoptosis has indicated 
the possible activation of the extrinsic, death-receptor-mediated pathway. 
The extrinsic apoptotic pathway is elicited by ligation of the death-inducing 
ligands to the death receptors which are present on the cell surface. Death receptors 
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are members of the TNF receptor superfamily which have been identified to have 
broad range of biological functions including cell death and survival regulation 
(Walczak and Krammer, 2000). Members of this family are entrusted with the ability 
to transmit death signals by the possession of an 80-amino-acid cytoplasmic domain 
called the 'death domain' (Bossen et al., 2006). Six members have been identified in 
this family, in which four of them have been well characterized in the induction of 
apoptosis: CD95 (APO-l/Fas), TNF receptor 1 (TNFRI), TRAIL-R1 (DR4) and 
TRAIL-R2 (DR5). By the engagement of death receptors to their corresponding 
ligands, which are CD95 ligand /FasL, TNFa and TRAIL, cell death signals from the 
cell surface to the cytoplasm can thus be elicited (Herr et al, 2000). 
As potential therapeutic targets, the three death-receptor/ligand pairs have been 
extensively studied. Having longer history than TRAIL, TNFa and Fas were found to 
possess antitumor activity in vitro and has been employed as a potential therapeutics 
in vivo (Ghobrial et al., 2005). Unfortunately, both cytokines possess different 
degrees of toxicity that impairs normal physiological functions, as discussed 
previously in Chapter 1. As a result, the tumor-specific TRAIL-mediated pathway 
becomes an attractive potential therapeutics, and has been receiving enormous 
attention. 
TRAIL appears to have specificity in triggering apoptosis towards tumor cells 
but not in normal cells (Suliman et al., 2001; Boehrer et al., 2006). The TRAIL 
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resistance observed in normal tissues is postulated to be the expression of the decoy 
receptors of TRAIL, DcRl andDcR2, which lack the ability to induce apoptosis 
(Zhang et al., 2001). Some of the TRAIL-resistant cancer cells were also identified 
with overexpression of the decoy receptors. On the other hand, it was found that the 
functional receptors, DR4 and DR5, were widely expression in different tissues, yet 
the expression was highly elevated when compared to that of normal cells (Kendrick 
et al., 2007). As a result, one of the determinants of TRAIL sensitivity of the cell is 
the net effect of death and decoy receptors that express and function on the cell 
surface. 
Owing to its minimal toxicity, TRAIL has been therefore targeting for 
therapeutic development. One of the therapeutic routes would be the administration 
of recombinant TRAIL. Several previous studies have suggested that recombinant 
TRAIL exhibited poor specificity for tumor cells and significant hepatotoxicity, 
which was related to the preparation method of the recombinant TRAIL. One 
construct of recombinant TRAIL, Apo2L/TRAIL (PRO 1762), is currently being 
evaluated in phase I clinical trials. (Genentech, South San Francisco, CA; Amgen, 
Thousand Oaks, CA) (Almasan and Ashkenazi, 2003). 
Being a promising therapeutic target, the synergism between TRAIL-mediated 
apoptosis and conventional chemotherapy has been extensively investigated. 
Accumulating evidence suggests that several cytotoxic agents, such as cisplatin, 
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paclitaxel, and adriamycin, administered in combination with TRAIL in vitro and in 
vivo enhance apoptosis (Komdeur et al., 2004; Lane et al., 2004). Furthermore, 
TRAIL-mediated apoptosis has also been shown to enhance the effects of ionizing 
radiation (Chinnaiyan et al., 2000; Buchsbaum et al, 2003). Observed from these 
findings, TRAIL would be a promising candidate for the development of combined 
anticancer regimen which may give rise to novel and effective treatments. 
As caspase-8 was found to be elicited in the baicalein induced apoptosis, the 
components of the extrinsic death receptor pathway were thus studied by 
immunoblotting. Moreover, exogenous TRAIL was added to the baicalein-treated 
cells to see if the phytochemical treatment could sensitize the cells to 
TRAIL-mediated apoptosis, which is evidenced to be a safe and effective mode of 
apoptosis. 
4.2 Materials and Methods 
4.2.1 Immunoblotting 
Detailed procedures of immunoblotting were described in section 3.2.2 with 
some modifications. In this section, primary antibodies against DR4 and TRAIL 
(both from BD Biosciences) were used under the dilution of 1:500 and 1:300 
respectively; primary antibodies against DR5 and (3-actin (both from Sigma) were 
used under dilution factor of 1:500 and 1:5000 respectively. 
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4.2.2 Determination of sub-lethal dose of exogenous TRAIL 
The sub-lethal dose of exogenous TRAIL on A375 cells was determined by 
MTT assay (details in section 2.2.2). Briefly, 1 x 104 cells per 100 i^l were seeded in 
each well of a flat-bottomed 96-well plate. After 24 h acclimatization, the cells were 
challenged with 0- 400 ng/ml TRAIL (Calbiochem, La Jolla, CA) for 12 h. MTT 
assay was then performed and the sub-lethal dose of TRAIL was estimated from the 
growth-inhibitory plot. 
4.2.3 Determination of the combinatory effect of exogenous TRAIL and 
baicalein 
The combinatory effect of exogenous TRAIL and baicalein on the growth and 
survival of A375 cells was also determined by MTT assay (details in section 2.2.2). 
Briefly, 5 x 103 cells per 100 jil were seeded in each well of a flat-bottomed 96-well 
plate. After acclimatization, the cells were then treated with 0- 100 \M of baicalein 
for 48 h. Twelve hours before the cells were harvested (i.e. after 36 h of incubation), 
the sub-lethal dose of TRAIL was added in each well of the plate and incubated for 
fUrther 12 h. MTT assay was then performed and the combinatory effect of 
exogenous TRAIL and baicalein was compared using the growth-inhibitory plots. 
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4.2.4 Statistical analysis 
Results were expressed as mean 土 S.D. and analyzed by Student's Mest. The 
level of significance was taken at p=0.05, 
4.3 Results 
4.3.1 Baicalein upregulates the expressions of death receptor 4 (DR4) and 
death receptor 5 (DR5) 
As mentioned in section 3.3.3, caspase-8 was found to be the major initiator of 
the apoptotic cascade induced by baicalein. As caspase-8 is the initiator caspase in 
the death receptor signaling branch of apoptosis, we therefore postulated that other 
components of the death receptor signaling pathway would also be modulated after 
the baicalein treatment. In this study, immunoblotting was used to determine the 
effects of baicalein on the expressions of two death receptors, DR4 and DR5, as well 
as their corresponding death signal ligand, TRAIL. The melanoma cells were 
incubated with baicalein at IC50 for 24 to 72 h. As shown in Fig. 4.1, both DR4 and 
DR5 levels elevated at 24 h of baicalein treatment, and the elevation persisted over 
the next 48 h when compared to their corresponding time controls. On the other hand, 
the TRAIL level was not significantly affected even after 72h of baicalein treatment. 
These findings demonstrated the selective effect of baicalein on the different 
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components in the death receptor apoptotic pathway. Also, it seemed that the 




































































































































































































































































































































































































































4.3.2. Baicalein sensitizes the melanoma cells to sub-lethal dose of exogenous 
TRAIL 
As elevation of the two death receptors, DR4 and DR5, were observed as early as 
24 h of baicalein treatment, which was concomitant with the activation of caspase-8, 
we hypothesized that the elevation might be able to sensitize the melanoma cells to 
the death signal. To testify the hypothesis, we first determined the sub-lethal dose of 
exogenous TRAIL by challenging the melanoma cells with various doses of TRAIL, 
from 0 to 400 ng/ml for 12 h. Incubation with exogenous TRAIL caused a 
dose-dependent inhibition of growth and survival in A375 cells, yet the inhibition 
became plateau after 25 ng/ml so that 44% inhibition of growth and survival was 
attained at the maximum dose of 400 ng/ml (Fig. 4.2). From the result, a sub-lethal 
dose of 12.5 ng/ml TRAIL was chosen to further investigate the sensitization effect of 
baicalein on the melanoma cells. At 12.5 ng/ml TRAIL, approximately 5% inhibition 
of cell growth and survival was detected, although the inhibition was not statistically 
significant. 
The melanoma cells were then challenged with 12.5 ng/ml TRAIL and various 
concentrations of baicalein to study the sensitization effect of the phytochemical on 
TRAIL treatment. Although the sub-lethal dose of TRAIL did not induce significant 
decrease in cell growth and survival in A3 7 5 cells, baicalein prominently sensitized 
the melanoma cells to the TRAIL treatment. The sensitization effect of baicalein on 
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TRAIL is depicted in Fig 4.3. The combinatory effect was the most prominent with 
12.5-50 |xM baicalein, at which the growth inhibition was at most doubled after 
exogenous TRAIL addition, when compared to the baicalein treatment alone. 
Taken together, baicalein can induce cell death in A375 cells via modulation of 
the extrinsic apoptotic pathway, in which the levels of death receptors DR4 and DR5 
are elevated. This elevation has functional significance since it can sensitize the cells 
to the TRAIL death signal. Therefore, combinatory effect does exist between baicalein 





















































































































































































































































































































































































































































































































































































































































































































In chapter 3, we demonstrated baicalein induced caspase-dependent apoptosis 
after cell cycle arrest in A375 cells. As caspase-8 was the earliest caspase activated in 
the signaling cascade, which suggested the involvement of death receptor-mediated 
signal transduction, other components of the extrinsic pathway were therefore 
studied. Being an initiator caspase, caspase-8 transduces various death signals 
through the formation of death-inducing signaling complex (DISC). After binding of 
the death ligand to its receptor, the complex is formed by the interaction between the 
death effector domain (DED) of procaspase-8 and the adaptor protein Fas-associated 
death domain (FADD) so that the inactive zymogen of caspase-8 is activated 
(Debatin and Krammer, 2004; Nunez et al., 1998). As the first step to evaluate the 
effect of baicalein on the receptor-mediated pathway, the expression of two death 
receptors, DR4 and DR5, as well as their corresponding death-inducing ligand, 
TRAIL were studied. Unlike other death-inducing ligands such as FasL and TNFa, 
which are generally toxic, TRAIL shows selective cytotoxic effect on cancer cells but 
not on normal cells (LeBlanc and Ashkenazi, 2003; Koschny et a/. ,2007). This 
differential response can be explained by the expression of death receptors of TRAIL 
only on cancer cells (Hersey and Zhang, 2001) and thus makes TRAIL 
mediated-apoptosis an attractive target to investigate and develop. Nonetheless, 
TRAIL has not yet been a commonly used anticancer agent due to the innate or 
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acquired resistance against TRAIL observed in many cancers (Ivanov and Hei, 2006), 
such as melanoma (Griffith et al., 1998), primary lymphoma and glioblastoma 
(Koschny et al., 2007). 
As shown in the immunoblotting results, baicalein elevated both DR4 and DR5 
in the melanoma cells as early as 24 h of treatment. This elevation was compatible to 
the activation of caspase-8 in a temporal manner which indicated a causal link might 
exist between death receptor elevation and caspase-8 activation in the 
baicalein-induced apoptosis. Ivanov and Hei (2006) proposed that an effective 
TRAIL-mediated signaling in cancer cells should have the following requirements: 1) 
The death-inducing ligand, i.e. TRAIL, either exogenous or induced surface 
expression; 2) sufficient surface expression of DR4/5 to accomplish effective 
apoptosis induction by receptor oligomerization or DISC formation and 3) effective 
repression of anti-apoptotic proteins. With reference to these three major criteria of 
TRAIL-induced apoptosis, baicalein seems to enhance initiation of the extrinsic 
apoptotic pathway through upregulation of death receptors. As more DR4 and DR5 
were expressed in the baicalein-treated cells, trimerization of the receptors and thus 
the subsequent DISC formation were facilitated. This resulted in the activation of 
caspase-8 and onset of the apoptotic cascade. 
To testify the functional significance of the baicalein-induced expression of 
DR4 and DR5, the baicalein-treated melanoma cells were challenged with a 
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sub-lethal dose of exogenous TRAIL to see if baicalein could sensitize the melanoma 
towards a non-cytotoxic dose of TRAIL. Since the cellular response towards TRAIL 
depends on the histotype of cells and the preparation method of the death ligand 
(LeBlanc and Aschkenazi, 2003), the sub-lethal dose of TRAIL specific for A375 
cells in this study was first determined. Revealing from the dose-response curve of 
A375 to TRAIL, the growth-inhibition occurred dose-dependently, which become 
plateau with 25 ng/ml or higher doses. A similar pattern of dose-response of A375 
cells to TRAIL was also reported (Kurnabov et al., 2007). From our results, the 
sub-lethal dose of 12.5 ng/ml TRAIL was selected, which was the maximum 
concentration of TRAIL that did not cause a statistically significant inhibition of the 
growth and viability of A375 cells (>95%). 
Human malignant melanoma A3 75 has been previously studied of having a 
consistent expression of both DR4 and DR5, and was classified to be a 
TRAIL-sensitive cell line (Kurbanov et al., 2005). This is coherent with our findings 
that both DR4 and DR5 were constitutively expressed in untreated A375, as well as 
its responsiveness to TRAIL inhibition. As predicted from our hypothesis, baicalein 
sensitizes the melanoma cells and exhibits a combinatory effect with TRAIL. For 
instance, after the cells have been treated with 12.5 JIM baicalein, even the sub-lethal 
dose of TRAIL could further reduced the growth and survival of the cells by 2-fold 
when compared to the baicalein-treated cells. 
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The combinatory effect between baicalein and TRAIL may be explained by the 
elevated DR4 and DR5 expression induced by baicalein. Several phytochemicals 
have also been reported to enhance DR4 and DR5 expression in cancer cells, such as 
sulforaphane which is abundant in cruciferous vegetables (Matsui et al, 2006); and 
quercetin that can be widely found in vegetables and fruits (Chen et al., 2007). 
However, according to our knowledge, we are the first group to show that baicalein 
can sensitize melanoma cell and exhibit combinatory effect with TRAIL to inhibit its 
growth. 
Taken together, baicalein is able to augment the apoptotic effect of TRAIL in 
A375 cells by elevating DR4 and DR5 levels. This suggests an attractive anticancer 
mechanism that, being a neoplasm-specific cytotoxic agent (section 2.3.2), baicalein 
is able to upregulate expression of DR4 and DR5 in the melanoma cells, and thus 
sensitizes the cancer cells to a non-cytotoxic level of TRAIL. Combinatory effect of 
this phytochemical with the novel therapeutic agent TRAIL is therefore worth 
investigating for development of new anticancer regimen. 
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Chapter 5. Effects of Baicalein on the Intrinsic Apoptotic 
Pathways in Human Melanoma A375 Cells 
5.1 Introduction 
The apoptotic route that undergone by dying cells could be delineated by 
analyzing the activation of various caspases, as previously mentioned in Chapter 3. 
This led our investigation in the extrinsic apoptotic pathway in the baicalein-treated 
melanoma cells, owing to the early activation of caspase-8. To this end, the 
baicalein-induced apoptosis was found to be mediated via the extrinsic 
death-receptor pathway, primarily through the elevation of death receptors. 
In addition to the activation of caspase-8 in baicalein-treated cells, caspase-9 
was also found to be activated (Chapter 3). Besides the initiation role played by 
caspase-8 in the extrinsic apoptotic pathway, caspase-9 is also an initiator caspase in 
the intrinsic mitochondrial pathway (Kumar, 2007). Similar to the activation of 
caspase-8, the activation of caspase-9 also suggested the possibility of the elicitation 
of the intrinsic mitochondrial pathway. 
The intrinsic apoptotic pathway is triggered by different kinds of stresses, 
compared with that of the extrinsic pathway which is ligand-receptor mediated 
(Crighton and Ryan, 2005). Upon the reception of the death-inducing stress signals, 
series of biochemical events occur and ultimately converge in the mitochondria. 
There are several morphological and biochemical features characterized the 
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mitochondrion-mediated apoptosis such as the occurrence of mitochondrial 
membrane permeabilization (MMP) and the release of cytochrome c (Budihardjo et 
al., 1999). As mitochondrial dysfunction and the subsequent release of apoptogenic 
factors mark the "point of no return" in apoptosis (Hangartner, 2000). Therefore, the 
loss of mitochondrial membrane integrity is an indication of the onset of the 
mitochondrion-mediated apoptosis. 
There are several analytical methods available for the detection of MMP, yet the 
most commonly employed method is the detection of mitochondrial membrane 
depolarization. Under normal physiological condition, the inner mitochondrial 
membrane is nearly impermeable to all ions, which allows the building up of proton 
gradient necessary for oxidative phosphorylation (Kroemer et al., 1998). Therefore, 
the maintenance of the proton gradient within the mitochondria is an indicator of 
normal mitochondrial functions. Once the intrinsic apoptotic pathway is initiated, the 
mitochondrial membrane is perforated and therefore the mitochondrial membrane 
potential can no longer be maintained. Therefore the dissipation of mitochondrial 
membrane potential is a good indicator of MMP, which is a hallmark of intrinsic 
mitochondrion-mediated cell death (Marchetti et al., 1996). 
JC-1 flow cytometric analysis 
The detection of mitochondrial membrane depolarization by flow cytometry 
with cationic lipophilic dyes has been a convenient analytical tool to assess the 
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occurrence of MMP. There are several dyes available for the purpose, such as 
Rhodaminel23 (Rhl23), DiOC6 and JC-1. However, drawbacks of some dyes have 
been identified. For instance, apoptotic cells tend to exhibit an increase in 
fluorescence obtained with Rhl23 caused by mitochondrial swelling (Zuliani et al., 
2003). As a result, the choice of membrane integrity fluorochromes would be critical. 
In this context, the use of fluorochrome JC-1 (6'-tetrachloro-l, 3, 
3' -tetraethylbenzimidazolylcarbocyanine iodide) would be an appropriate choice for 
the detection of mitochondrial membrane dissipation. Under normal circumstances, 
JC-1 exists as J-aggregates in the inner, polarized mitochondrial membrane and emits 
red fluorescence of 590 nm. As the mitochondrial membrane potential drops under 
apoptotic conditions, J-aggregates disintegrate and JC-1 exists as its 
green-fluorescent monomeric form, emitting fluorescent signal at 527 nm. Therefore 
the dissipation process can be visualized on the bivariate DNA histogram by 
observing the shift of red color to green color under the same excitation wavelength 
of 488nm (Salvioli et al,, 1997; Zuliani et al, 2003). The ratio of green to red 
fluorescence emitted by JC-1 is therefore an indicator of extend of mitochondrial 
membrane depolarization (Bedner et al., 1999). 
To investigate the mitochondrial membrane depolarization induced by baicalein 
in A375 cells, JC-1 was applied to examine the mitochondrial membrane potential. It 
is well known that several stimuli induce a decrease in the mitochondrial 
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transmembrane potential, and this indicates the mitochondrial membrane is 
permeabilized and thus allows the release of apoptogenic factors, such as cytochrome 
c (Crompton, 1999). Therefore in order to substantiate the occurrence of MMP, 
detection of cytosolic cytochrome c was also performed by immunoblotting. 
The Bcl-2 family of proteins has been regarded as the central regulator of 
mitochondrial pathway (Ghobrial et al., 2005). As a result, the expression of several 
well-characterized Bcl-2 family proteins in baicalein-treated cells was also 
investigated in the present study by immunoblotting. The Bcl-2 family can be 
sub-divided into anti-apoptotic (e.g. Bcl-2, Bcl-xL etc.) and pro-apoptotic (e.g. Bax, 
Bad etc.). The activated members from the two sub-group of the Bcl-2 family exert 
their functions at mitochondria by interacting with one another and induce 
permeabilization of the outer mitochondrial membrane. The extrinsic pathway can be 
connected the intrinsic pathway via the Bcl-2 family, BH-3 only member Bid. 
Activated caspase-8 of the extrinsic pathway, Bid can be cleaved and truncated (i.e. 
tBid). The tBid formed then translocates to mitochondria and enhances the 
oligomerization of the pro-apoptotic Bcl-2 family members, such as Bax and Bak, 
leading to outer mitochondrial membrane permeabilization (Kandasamy et al,, 2003; 
Schwarz et al., 2007). The induction of apoptosis by baicalein via the modulation of 
the Bcl-2 family proteins has been previously report in other types of cancer. For 
instance, the apoptosis induced by baicalein in breast cancer cells was elicited via the 
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reduction of expression of the antiapoptotic Bcl-2 and Mcl-1 (Tong et al,, 2002). 
Nonetheless, the regulation of Bcl-2 family proteins might not be obligatory in the 
baicalein-induced mitochondrial pathway, especially the induction of MMP, as 
previously reported by Wang et al. (2004). 
Though Bcl-2 family proteins are the central regulator of mitochondrial 
dysfunction, other mechanisms that leads to MMP may also elicited by baicalein in 
the melanoma cells. In this context, the role of ROS in the mitochondrion-mediated 
apoptosis should therefore be investigated. Reactive oxygen species (ROS) has been 
recently identified to play a regulatory role in apoptosis (Ott et al., 2007). It is 
formed as a natural byproduct of the normal metabolism of oxygen. Mitochondria, 
the power house of the cell, would therefore be the primary site of production of 
ROS by oxidative phosphorylation (Storz, 2007). Despite the available antioxidative 
systems that can eradicate the excess ROS from the cells, the imbalance of the 
production and removal of ROS will lead to devastating damages. Ironically, the 
major producer of cellular ROS, the mitochondria would be the primary sites 
damaged by plethora of ROS. 
ROS exerts its devastating effects by targeting different machineries in the 
mitochondria. The mitochondrial DNA (mtDNA), which is free of histone and in 
close proximity with the ROS produced, is more vulnerable to oxidative damage than 
other components in the same organelle(Orrenius et al., 2007). ROS also perturbs the 
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normal electron transport chain by oxidixing the ion-carrying proteins and related 
enzymes (Fridovich, 1997). As a potent oxidizing agent, ROS is capable in oxidizing 
the phospholipids on the mitochondrial membrane, which directly affects the 
membrane integrity. Consequently, the mitochondrial membrane potential can no 
longer be maintained, and leads to the impairment of mitochondrial functions 
(Venditti et al, 2004). 
To this end, the role of ROS in the mitochondrion-mediated pathway in 
baicalein-treated cells was also elucidated, aiming at revealing any possible 
mechanisms involved. To begin with, the intracellular ROS level was first detected 
by the application of a flurogenic probe, 2丨,7丨-dichlorofluorescin diacetate 
(H2DCFDA) and the addition of antioxidant Trolox™ to delineate the possibility of 
baicalein-induced ROS on mitochondrial membrane depolarization and cytochrome c 
release. 
ROS production assay by H^DCFDA 
The use of H2DCFDA is a popular method for measuring the production of 
ROS by a variety of cell types, in both flow-cytometric and spectrofluorometric 
systems. This method is frequently employed due to its simplicity and high 
sensitivity. Also, it is relatively inexpensive when compare to the traditional 
approaches of ROS measurement, such as assaying for the reduction of cytochrome c 
by superoxide (Krejsa and Schieven, 2000). H2DCFDA is able to cross the plasma 
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membrane and enter the cell, in which the probe will be hydrolyzed by cellular 
esterases to produce 2',7'-dichlorodihydrofluorescein (H2DCF). The de-acetylated 
form of the probe is then susceptible to oxidation, generating a fluorescent product, 
2',7'-dichlorofluorescein (DCF). Accumulation of DCF therefore indicates the 
production of redox-active substances (Brubacher and Bols, 2001). The resulting 
output of ROS is measured as the increase in fluorescence associated with oxidation 
of the probe, where this relationship between DCF and fluorescence is linear over a 
broad concentration range, allowing for expression of the relative level of ROS 
production in arbitrary units. 
5.2 Materials and methods 
5.2.1 Analysis of mitochondrial membrane potential 
The change of mitochondrial membrane potential after baicalein treatment was 
detected by using the fluorescent potential sensor probe, 
5，5，,6,6，-tetrachloro-1,1 ’,3,3 ’-tetraethylbenzimidazolylcanbocyanine iodide (JC-1 ； 
Molecular Probes, Eugene, OR). After harvest and thorough washing, 1 x 106 treated 
or untreated cells were incubated with lOjig/ml JC-1 for 15 minutes at 37 °C prior to 
analysis on a flow cytometer under an excitation wavelength of 488 nm. Data were 
expressed as the change of red/green fluorescence intensity ratio. 
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5.2.2 Fractionation of cell lysates into cytosolic and mitochondrial fractions for 
immunoblotting 
To obtain mitochondrial and cytosolic fractions, the melanoma cells were 
homogenized and fractionated by the Cytosol-Mitochondria Fractionation kit 
(Calbiochem). Briefly, 1 x 107 cells were harvested and resuspended in cytosol 
extraction buffer (provided) supplemented with protease inhibitors for 10 minutes on 
ice, and disrupted using a dounce tissue grinder. Homogenates were then clarified at 
700g for 10 minutes at 4 °C. The supernatants were further centrifuged at 10 OOOg for 
30 minutes at 4 °C. The resulting supernatants were recovered as cytosolic fraction 
and the pellets were resuspended in mitochondrial extraction buffer (provided) to 
yield the mitochondrial fraction. The protein content in the fractions were quantified 
by BCA assay (details in section 3.2.2b) and were stored under -20°C prior use. 
5.2.3 Immunoblotting 
Detailed procedures of immunoblotting were described in section 3.2.2 with 
some modifications. In this section, primary antibodies against Bcl-xL, Bax, Bad, 
Bim, Bid and cytochrome c (all from Cell Signaling) were used under the dilution of 
1:1000; whereas primary antibodies against Bcl-2 (BD Bioscience) and P-actin 
(Sigma) were used under dilution factor of 1:250 and 1:5000 respectively. 
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5.2.4 Determination of cellular reactive oxygen species (ROS) production 
Total cellular ROS production was measured using 2',7'-dichlorofluorescin 
diacetate (H2DCFDA; Molecular Probes). Briefly, 5x 105 cells were harvested and 
washed before staining with 10 JIM H2DCFDA in dark at 37 °C for 1 h. Cells were 
pre-treated with 500 mM hydrogen peroxide (H202; Sigma) 5 h prior collection of 
cells, which acts as a positive control. After incubation, the cells were washed and 
the fluorescence generated was measured by a fluorescence plate reader (Tecan) with 
an excitation wavelength of 460 nm and an emission wavelength of 530 nm. 
Fluorescence values generated in each treatment was converted into fold changes of 
the control. 
5.2.5 Verification of ROS generation via the addition of Trolox™ 
Trolox™ (Sigma), a water soluble vitamin E analogue, was co-administrated 
with baicalein to verify the effect of cellular ROS. Before baicalein treatment, cells 
were pre-treated with 100 JIM Trolox™ for 1 h. After pre-incubation, baicalein at 
IC50 was added to further incubate for 48 h. The cells were then harvested for 
cytosolic/ mitochondrial cell fractionation (section 5.2.2) followed by 
immunoblotting (section 3.2.2) as well as for measurement of ROS (section 5.2.3). 
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5.2.6 Statistical analysis 
Results were expressed as mean 士 S.D. and the statistical significance of the 
difference between control and the treatment groups was determined by one-way 
ANOVA followed by Tukey's test for multiple comparisons. The level of significance 
was taken at p=0.05. 
5.3 Results 
5.3.1. Baicalein induces mitochondrial membrane depolarization 
As mentioned in section 3.3.2, baicalein first induced activation of caspase-8, 
which is the initiator caspase of the extrinsic or death receptor apoptotic pathway; 
followed by caspase-9, which is the initiator caspase of the intrinsic or mitochondrial 
pathway. To further substantiate the ability of baicalein in activating the 
mitochondrial apoptotic pathway, mitochondrial membrane depolarization, an early 
hallmark event of mitochondrial-mediated apoptosis, was investigated by JC-1 flow 
cytometry. Effect of baicalein on the mitochondrial membrane potential was 
determined after 24，48 and 72 h of incubation. Under normal circumstances, JC-1 
exists as J-aggregates in the inner, polarized mitochondrial membrane and emits red 
fluorescence. As the mitochondrial membrane potential drops under apoptotic 
conditions, J-aggregates disintegrate and JC-1 exists as its green-fluorescent 
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monomeric form. The ratio of green to red fluorescence emitted by JC-1 is therefore 
an indicator of extend of mitochondrial membrane depolarization (Bedner et al” 
1999). 
As shown in Fig. 5.1，control cells showed a low mean ratio of green to red 
fluorescence after staining with JC-1, At 48 h of treatment, baicalein induced a shift 
of cell population to the right, indicating that more green fluorescence was emitted 
and the mitochondrial membrane was depolarized [Fig. 5.1 a ii.) vs b ii.)], For a 
longer period of baicalein treatment, i.e., 72 h, there was even a drop of mean red 
fluorescence level, suggesting that the mitochondria were not able to function 
properly so that they were no longer negatively charged to accumulate the 
J-aggregates of JC-1 in the mitochondria. This showed that late phase apoptosis or 
















































































































































































































































































































































































































































































5.3.2. Cytochrome c is released in the baicalein-induced mitochondrial 
membrane depolarization 
As mitochondrial membrane depolarization was observed at 48 h after baicalein 
treatment in A375 cells (section 5.3.1), release of apoptogenic factors from the 
mitochondrial intermembrane space to the cytosol was therefore investigated to 
consolidate the occurrence of mitochondrial membrane depolarization. Cytochrome c 
is an electron carrier found normally in mitochondria and is released into the cytosol 
as an apoptogenic factor when mitochondria-mediated apoptosis occurred (Yang et 
al., 1997) Release of cytochrome c into the cytoplasm was therefore studied by 
immunoblotting in this study. This was achieved by fractionating the cell lysate into 
cytosolic and mitochondrial fractions through specific lysis, mechanical disruption of 
cells and differential centrifugation. Specific antibody against cytochrome c was used 
to detect the relative amount of cytochrome c in both fractions. At 48 h of treatment, 
more cytosolic cytochrome c was found in the baicalein-treated cells than in the 
control cells, together with a decrease of mitochondrial cytochrome c in 
baicalein-treated cells when compared to the control cells. (Fig. 5.2) 
Taken together, it was found that baicalein had induced the intrinsic apoptotic 
pathway in A375 cells, evidenced by occurrence of mitochondrial membrane 
























































































































































































































































































































































































































5.3.3. Baicalein does not elicit the intrinsic apoptotic pathway via 
modulation of some better-characterized Bcl-2 family proteins in A375 
cells 
As mentioned in section 3.3.2 and 5.3.1, baicalein may found to elicit the 
mitochondrial apoptotic pathway and thus activation of caspase-9. Since the 
mitochondrial apoptotic pathway is controlled by Bcl-2 family proteins (Tudor et al., 
2000), six better-characterized proteins were measured in the baicalein-treated cells. 
The melanoma cells were treated with baicalein at IC5o for 24 to 72 h, and expression 
of anti-apoptotic members Bcl-2 and Bcl-xL； and the pro-apoptotic members Bax, 
Bad, BimEL, and Bid was revealed by immunoblotting. However, baicalein neither 
significantly depleted level of the anti-apoptotic proteins (Fig. 5.3) nor prominently 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.4. Baicalein induces ROS production 
As mentioned in section 5.3.3, baicalein did not modulate at least some 
better-characterized Bcl-2 proteins to release cytochrome c from mitochondria. In 
addition to the well-established role of the Bcl-2 family proteins that regulate the 
mitochondrial release of apoptogenic factors, ROS-triggered mitochondrial 
permeability transition also provides an alternative for the release of apoptogenic 
factors from mitochondria (Rosse et al., 1998). Owing to the lack of evidence in the 
modulation of Bcl-2 family proteins by baicalein, we therefore hypothesized that the 
mitochondrial membrane perforation and the subsequent cytochrome c release would 
be a ROS-mediated event. To test this hypothesis, ROS level in the baicalein-treated 
cells was measured by DCF spectrofluorometry. Furthermore, Trolox™, a water 
soluble vitamin E analogue that can penetrate and protect cells from ROS, was also 
given to the baicalein-treated cells to retard generation of and any response caused by 
ROS. The amount of ROS produced in A375 cells after incubation with baicalein and 
Trolox™ was directly measured by H2DCFDA. H2DCFDA is a cell penetrating dye 
that will be oxidized by ROS to highly fluorescent DCF, so that the intensity reflects 
the level of cellular ROS production. As illustrated in Fig 5.5, the addition of 
baicalein prominently elevated the total cellular ROS level by 1.7-fold of the control 
level, suggesting that the phytochemical did induce ROS production in the cells. 
Addition of Trolox™, on the other hand, suppressed the baicalein-induced ROS 
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production by more than 50%. Similar suppression by Trolox™ was also observed in 










































































































































































































































































































































































































































































































5.3.5. Baicalein induces mitochondrial membrane permeabilization via 
ROS-mediated mechanisms 
As found in section 5.3.4, baicalein induced ROS production in A375 cells that 
could be inhibited by Trolox™. To study the role of ROS in the baicalein-induced 
mitochondrial apoptosis, the melanoma cells were incubated with different 
combinations of baicalein and Trolox™, and the mitochondrial membrane 
depolarization, a key step in the mitochondrial apoptotic pathway was measured. 
Result from JC-1 analysis revealed that addition of Trolox™ could inhibit the 
baicalein-induced mitochondrial membrane depolarization. After 48 h baicalein 
incubation, about 89% of the melanoma cells had depolarized mitochondrial 
membrane potential (Fig. 5.6). Co-incubation of 100 jiM Trolox™ with baicalein at 
IC50 drastically reduced depolarized cells to about 2 7 % only. 
Compatible result was also obtained in the mitochondrial cytochrome c release 
after baicalein and Trolox™ treatments. As demonstrated in Fig 5.7, the baicalein 
-induced release of cytochrome c after mitochondrial membrane depolarization was 
restored back to the control level by Trolox™ co-treatment. 
In summary, baicalein induced apoptosis in A375 cells, mediated by the intrinsic 
apoptotic pathway with mitochondrial membrane depolarization and release of 
cytochrome c into the cytoplasm. However, modulation of proteins from the Bcl-2 
family, a common initiator of intrinsic apoptotic pathway, was not observed. Instead, 
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cellular ROS level was elevated and behaved as an initiator of the mitochondrial 

















































































































































































































































































































































































































































































































































































































































































































































































































































































In chapter 4 we demonstrated that the early phase of the baicalein-induced 
apoptosis was executed via the death receptor pathway, with the elevation of death 
receptors DR4 and DR5, and activation of caspase-8. Furthermore, it seemed that 
during the exacerbation phase of the cell death, the mitochondrial pathway was 
involved. 
The activation of caspase-9 is the first proteolytic signal in the intrinsic 
apoptotic pathway (Riedl and Salvesen, 2007). Unlike the initiator caspase-8 in the 
extrinsic apoptotic pathway that is activated by transmembrane receptor, caspase-9 is 
activated by the cytosolic complex called apoptosome. Apoptosome composes of 
several molecules, including Apaf-1, cytochrome c, ATP or 2'-deoxyATP (dATP) 
(Shi, 2006). The apoptosome formed will then recruit and activate caspase-9, which 
performs the subsequent cleavage of apoptotic substrates. In this circumstance, the 
release of cytochrome c from mitochondria into the cytosol becomes critical, not 
only because cytochrome c is one of the components of apoptosome, but also it 
triggers the self-inhibited and monomeric Apaf -1 molecules to oligomerize and 
initiate the apoptosome formation (Riedl et al., 2005). Hence, the release of 
mitochondrial cytochrome c to the cytosol is a key event of execution of the intrinsic 
apoptotic pathway. 
Cytochrome c is an electron carrier that participates in the oxidative 
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phosphorylation under normal physiological conditions (Slee et al., 1999). As a 
mobile electron carrier, cytochrome c binds electrostatically to negatively charged 
surfaces of respiratory complexes at the outer face of the inner membrane (Kannt et 
al., 1998). Since electrons flow rapidly down the respiratory chain, cytochrome c can 
freely shuttle among each complex and is not tightly bound. Therefore, it is normally 
restricted to the intermembrane space by the integrity of the mitochondrial membrane 
(Crompton, 1999). During the execution of apoptosis, the mitochondrial membrane 
will lose its integrity and therefore apoptogenic factors, such as cytochrome c will be 
released to the cytosol. There are several proposed mechanisms for this 
mitochondrial membrane permeabilization (MMP), and the actual mechanisms 
underlying the release of apoptogenic factors seem complex and controversial. MMP 
can be further sub-divided into permeabilization of inner and outer membranes, 
which have distinct characteristics and significance in the mitochondrion-mediated 
apoptosis (Schwarz et al., 2007). Nonetheless, the ultimate consequences would be 
the loss of mitochondrial membrane integrity and release of apoptogenic factors 
(Kroemer et al., 2007). In this aspect, we detected the change of mitochondrial 
potential with flow cytometry as an MMP indicator. 
Under normal physiological condition, the inner mitochondrial membrane is 
nearly impermeable to all ions, including protons. This allows the building up of 
proton gradient necessary for oxidative phosphorylation which drives ATP synthesis. 
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The inner mitochondrial transmembrane potential ( A ^ m ) is a result of the charge 
imbalance across the inner membrane. Therefore, the maintenance of the proton 
gradient within the mitochondria is of vital importance for cellular survival (Kroemer 
et al., 1998). Although a temporary loss of the A ^ m may occasionally occur in 
normal conditions (Zoratti and Szabo，1995)，a long-lasting or permanent A^m 
dissipation is often associated with cell death apoptosis (Marchetti et al., 1996). As a 
result, MMP is also a good indicator of apoptosis. 
During the exacerbation phase of the baicalein-induced apoptosis, involvement 
of caspase-9 was further substantiated by cytochrome c release and loss of 
mitochondrial membrane potential. It was found that after 48 h of baicalein treatment, 
there was a prominent loss of mitochondrial membrane potential. The loss of 
potential was accompanied by the release of cytochrome c into the cytosol, indicating 
the possible formation of apoptosome and thus activation of caspase-9. Supporting 
by these findings, we believed that baicalein induced not only the extrinsic death 
receptor pathway (Chapter 4), but also the intrinsic mitochondrial apoptotic pathway, 
especially during the exacerbation phase of the induced apoptosis, in A375 cells. 
After validating the elicitation of the intrinsic mitochondrial pathway in the 
baicalein-induced apoptosis, the next question await to be answered would be the 
regulators that initiate this signaling cascade. Bcl-2 family proteins are well-studied 
for their central regulatory roles in the mitochondrial-mediated apoptosis. Bcl-2 
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family proteins share conserved domains, namely the Bcl-2 homology (BH) domains. 
This family can be sub-divided into anti-apoptotic (e.g. Bcl-2, Bcl-xL etc.) and 
pro-apoptotic (e.g. Bax, Bad etc.) proteins so that they interact with one another to 
regulate apoptosis. The activated pro-apoptotic members of the Bcl-2 family exert 
their ftmction at mitochondria by inducing permeabilization of the outer 
mitochondrial membrane. This permeabilization results in the release of proapoptotic 
factors from the intermembrane space, such as cytochrome c, to activate effector 
caspases (Wang, 2001). The extrinsic pathway can be connected the intrinsic 
pathway via the Bcl-2 family, BH-3 only member Bid. Under the action of activated 
caspase-8 in the extrinsic pathway, Bid can be cleaved and truncated (i.e. tBid). The 
tBid formed then translocates to mitochondria and enhances the oligomerization of 
the pro-apoptotic Bcl-2 family members, such as Bax and Bak，leading to outer 
mitochondrial membrane permeabilization (Kandasamy et al., 2003; Schwarz et al., 
2007). In the extrinsic pathway, this permeabilization serves as an amplification loop 
for the activation of effector caspases (Gross et al., 1999). 
In this study, several proteins of the Bcl-2 family, which have been commonly 
reported to be the central regulators of mitochondrial apoptosis, were studied by 
immunoblotting. These include anti-apoptotic Bcl-2 and Bcl-xL； pro-apoptotic Bax, 
Bad and BimEL; as well as the pathway-linker Bid. Out of our expectation, none of 
the Bcl-2 family members studied had significant change after baicalein treatment, 
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even after prolonged treatment of 72 h when extensive apoptosis occurred (chapter 3). 
The immunoblotting results seemed not compatible to the previous findings and 
traditional beliefs about the loss of mitochondrial integrity and release of cytochrome 
c, by the Bcl-2 family members. 
In fact, besides Bcl-2 family proteins, intracellular ROS has been recently 
identified to play a regulatory role in apoptosis (Ott et al., 2007). The undesirable 
condition brought by ROS is the pose of oxidative stress on the cells. The generation 
of ROS is unavoidable, and the major source of ROS is the oxidative 
phosphorylation in mitochondria. With damaging effects on cellular macromolecules, 
ROS is constantly eradicated by antioxidative systems. Problems arise at times when 
imbalance occurred between generation of ROS and antioxidative systems, resulting 
in the generation of oxidative stress (Liu et al., 2002). The ability of ROS to initiate 
apoptosis is its devastating effect on cellular components, particularly those inside 
the mitochondria (Orrenius et al.’ 2007). The destructive effects include lipid 
oxidation that mostly affects membrane structures; damage of both nuclear and 
mitochondrial DNA and protein molecules (Fleury et al., 2002). In addition, ROS 
also perturbs the mitochondrial ionic balance and causes dissipation of the membrane 
potential, resulting in the release of apoptogenic factors from within (Kowaltowski, 
1996). 
The possibility that baicalein induces mitochondrial apoptosis via ROS 
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generation further is substantiated by previous findings. Baicalein has been reported 
to induce ROS-mediated mitochondrial dysfunction in human promyeolytic leukemia 
(Wang et al, 2004; Makino et al, 2006). We therefore hypothesized that ROS might 
involve in the initiation of the mitochondrial pathway in the baicalein-induced 
apoptosis. It was found that ROS was prominently elevated in the baicalein-treated 
cells. To confirm the involvement of ROS in the mitochondrial apoptosis, Trolox™ 
was used in the study. Trolox™ is the water soluble analogue of a- tocopherol, and is 
frequently used as a standard antioxidant in biochemical studies to compare the 
antioxidative capacity of compounds of interest (Poljsak and Raspor, 2007). 
Trolox™ was co-administered with baicalein to the melanoma cells to see if the 
antioxidant was able to reverse the mitochondrial apoptotic features brought by 
baicalein. Firstly, we found that Trolox™ was able to eradicate the elevation of ROS 
in baicalein-treated cells. For comparison, we also showed that Trolox1 could lower 
hydrogen peroxide (H202), which we had added to the cells to act as a positive 
control of ROS production. The antioxidant then rescued the mitochondrial 
membrane depolarization and release of cytochrome c caused by baicalein in A375 
cells. The restoration of normal mitochondrial potential gradient also ceased the 
cytochrome c release. 
Recapitulate the above findings, baicalein is able to induce apoptosis, firstly via 
the extrinsic death receptor pathway as previously discussed during the initiation 
117 
Chapter 6 
phase, which is then followed by the intrinsic mitochondrial pathway through the 
production of ROS during the exacerbation phase. 
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Chapter 6 General Discussion 
Cancer has become one of the most devastating diseases worldwide. According 
to the World Health Organization (WHO), malignant tumors were responsible for 12 
per cent of the nearly 56 million deaths worldwide from all causes in the year 2000 
(Mathers et al” 2001). Despite the continuous efforts made on new anticancer drug 
discoveries, some of the cancers remain poorly treated. The obstacles faced by cancer 
treatment attribute to the occurrence of multidurg resistance (Gottesman and Paston, 
1993), the metastatic properties of cancer cells (Aziz et al., 2003; Eccles and Welch, 
2007) and the lack of selective cytotoxicity of anticancer drug (de Bono et al 2003; 
Crighton and Ryan, 2004) which limit the drug dosage to a tolerable yet effective 
level. As a result, the urge of discovery of new antiproliferative therapeutics and 
cancer regimen has never been slowing down. 
Natural products have been regarded as important sources that could produce 
potential chemotherapeutic agents. Over 50% of anticancer drugs approved by the 
United States Food and Drug Administration (FDA) since 1960 were originated from 
the natural resources, especially from terrestrial plants (Kim and Park, 2002). 
Chemicals derived from plants have been used as major chemotherapeutics, such as 
taxol; or as adjuvants facilitating the treatments by conventional anticancer drugs. As 
a preventive measure, the importance of phytochemicals has been increasingly 
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recognized (Aziz et al., 2003; Surh, 2003). 
Regarding to the importance of new anticancer drug discovery from the natural 
source, Traditional Chinese Medicine (TCM) would represent a rich and attractive 
pool of bioactive chemicals that worth investigating (Chen et al., 2006). Because of 
the growing interest in therapeutic agents based on TCM, increasing effort has been 
directed towards scientific proof, clinical evaluation and molecular analysis of TCM 
(Chen et al., 2003). In fact, many phytochemicals have been isolated from TCM and 
have gained much attention in the medical community. Many of the selected 
phytochemicals have been extensively studied for the anticancer properties and 
health beneficial effects. The medicinal fungus ‘Ling Zhi’, Ganoderma Lucidum, has 
long been used as a folk remedy for promotion of health and longevity (Lin and 
Zhang, 2004). Extensive studies have unraveled the possible antitumor mechanisms 
of the fungus. Different bioactive constituents, such as the polysaccharide and 
triterpene fractions exert antiproliferative effects by immunomodulation (Lin et al, 
2003). In this study, the antiproliferative properties of another bioactive 
phytochemical, baicalein, was investigated. Baicalein is a flavone isolated from an 
anti-inflammatory TCM called Huang Qin, which is actually the dried root of 
medicinal herb Scutelleria baicalensis Georgi (Wang et al” 2004). In mainland 
China, S. baicalensis is used for treating upper respiratory infections, diphtheria, 
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nephritis, dysentery, scarlet fever and hepatitis. Being one of the bioactive 
components of the herb, baicalein has been reported to possess anti-viral, antioxidant 
and anti-inflammatory activities (Li et al., 2004). Recent studies have also shown 
that baicalein retarded cancer cell growth in vitro and in vivo. Baicalein was able to 
induced apoptosis in vitro in bladder cancer cell lines (Ikemoto et al., 2000) and 
breast cancer cell line (Po et al., 2002); in animal models, tumor regression was also 
observed for prostate carcinoma (Guo et al., 2004) and breast cancer (So et al, 1996). 
Despite of the extensive studies of the antitumor effects of baicalein, comprehensive 
investigation on its mechanisms are very limited. Being an efficacious phytochemical 
with potent anticancer and other beneficial effects, a detailed study on its mechanism 
should be elucidated to enrich our knowledge in drug discovery from the natural 
source. 
Baicalein was shown firstly in the present investigation to inhibit the growth of 
different human cancer cell lines, including malignant melanoma A375 and 
colorectal carcinoma Caco-2. However, baicalein did not induce significant growth 
inhibition in hepatocellular carcinoma HepG2, lung carcinoma A549, prostate 
carcinoma PC-3 and breast carcinoma MCF7. This differential activity of baicalein 
demonstrates that baicalein is not a broad-spectral cytotoxic compound, and its 
actions may depend on the histotype or molecular constituents of the cells. The 
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differential activity of baicalein was further validated with the normal skin fibroblast 
cell line Hs68. At the doses which baicalein prominently inhibited the melanoma cell 
growth, the normal skin cells were not significantly affected. This further 
substantiates the specificity on cell growth inhibition by baicalein. Consequently, 
human melanoma A375, being the most responsive cell line, was chosen for further 
studies. 
Responses of A375 cells to the antiproliferative and cytotoxic actions of 
baicalein seem to occur in a dose-dependent manner. To further analyze, we used 
DNA flow cytometry to examine the time effects of baicalein on cell cycle and 
apoptosis, the two main processes that could modulate tumor development. The 
results illustrated that the antiproliferative action of baicalein was associated with the 
primitive accumulation of cells at S phase of cell cycle shortly after 36 h of 
incubation. The S-phase arrest was accompanied by depletion of Gi cells, suggesting 
that some cells were delayed or forced to complete the cell cycle without re-entering 
Gi phase. This aberrant termination of cell cycle designated some of the arrested 
cells to undergo apoptosis. In parallel with the S-phase arrest, the apoptotic 
population accumulated exponentially under prolonged baicalein treatment. The 
appearance of apoptotic cells shortly after S-phase arrest suggested the importance of 
apoptosis induction in the cell growth control induced by baicalein. As a result, the 
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apoptotic mechanisms of baicalein-induced cell death were further investigated. 
The incidence of apoptosis was revealed in the flow cytometric analysis by the 
presence of hypodiploid or apoptotic population in the DNA histogram. The 
apoptotic population was identified by flow cytometry according to the occurrence of 
DNA fragmentation, which is one of the morphological hallmarks of apoptosis. 
Apoptosis was characterized by several physical and biochemical features. Apoptotic 
cells would have a characteristic morphology with chromatin condensation, DNA 
fragmentation, and cell shrinkage (Ziegler and Groscurth, 2004). Biochemically, 
caspases will be activated to execute the subsequent proteolysis and breaking down 
of the cells (Gilmore et al., 2000). The baicalein-induced apoptosis was confirmed 
biochemically by the study of caspase activation via immunoblotting. It was found 
that baicalein induced caspase-dependent apoptosis of the melanoma cells, with 
activations of caspase-8, caspase-9 and caspase-3. Among the three activated caspase, 
caspase-8 was the earliest caspase to be activated, i.e. after 24 h treatment, whereas 
caspase-9 and caspase-3 were both activated after 48 h of treatment. This sequential 
activation has delineated the possible apoptotic cascade involved. In this case, as 
caspase-8 was the earliest activated initiator caspase, the extrinsic apoptotic pathway 
was then investigated. 
Caspase-dependent apoptosis is executed by the initiation of two pathways: the 
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death-receptor-mediated extrinsic pathway and the mitochondrion-mediated intrinsic 
pathway. Caspase-8 is the initiator caspase of the extrinsic pathway, and it is 
activated by the DISC formation with the death-inducing ligand, death receptor, 
death-domain containing molecule and procaspase-8 (Kurbanov et al” 2005). As 
caspase-8 was found to be activated, we hypothesized that the death receptor/ligand 
interaction might be enhanced. To testify this hypothesis, expression of the 
components of the death receptor pathway was investigated by immunoblotting. In 
this study, TRAIL-mediated pathway was chosen for further studies. TRAIL is a 
member of the TNF family of cytokines that can initiate cell death. Unlike other 
family members such as TNFa and FasL which possess general cytotoxicity, TRAIL 
seems to exert its death-inducing effect specifically in neoplastic cells, rather than in 
normal cells (MacFarlane, 2003). This specificity in action has imposed an attractive 
character for TRAIL to be developed into new therapeutic regimen. Results from the 
immunoblotting illustrated that baicalein elevated the two TRAIL receptors, DR4 and 
DR5, but not their ligand TRAIL. This finding supports our postulation that baicalein 
may upregulate DR4 and DR5 to activate caspase-8 and the extrinsic apoptotic 
pathway. 
In order to evaluate the functional significance of the elevated receptors, 
sub-lethal dose of TRAIL, i.e.12.5 ng/ml, was co-administered to see if baicalein 
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could sensitize A375 cells to the growth-inhibitory effect of TRAIL. According to 
our knowledge, we are the pioneer group to show that synergism exists between 
baicalein and TRAIL so that the growth inhibition on the melanoma cells could be 
enhanced by almost 2-fold if they are administered together. This sensitization may 
probably due to the enhanced expression of DR4 and DR5 after baicalein treatment, 
yet ftirther investigation is needed to prove the hypothesis. 
The activation of caspase-8 has led us to the investigation of the extrinsic 
pathway and so do the activation of caspase-9. The activation of caspase-9 is a strong 
indicator of the elicitation of the mitochondrion-mediated apoptosis. Self-activation 
of caspase-9 relies on the close proximity between procaspase-9 molecules that 
brought by apoptosome (Hajra and Liu, 2004). Apoptosome composes of several 
molecules of Apaf-1, cytochrome c and ATP molecules (Shi, 2006). For apoptosome 
formation, presence of cytosolic cytochrome c is critical. Release of cytochrome c 
from mitochondria indicates mitochondrial dysfunction, and molecules for 
apoptosome formation. Hence, the release of mitochondrial cytochrome c to the 
cytosol is a key event of execution of the intrinsic apoptotic pathway. To detect the 
execution of the mitochondrial pathway in baicalein-induced apoptosis, 
mitochondrial membrane potential and cytosolic cytochrome c were measured by 
flow cytometry and immunoblotting, respectively. We further demonstrated in this 
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study that there was mitochondrial membrane depolarization as early as 48 h of 
treatment, with concomitant release of cytochrome c. This implies that besides the 
death receptor pathway, the mitochondrial pathway is also executed in the 
baicalein-induced apoptosis in A375 cells. 
The next question awaits to be revealed would be what the regulators of 
mitochondrial dysfunction are in the baicalein-induced apoptosis. The Bcl-2 family is 
the central regulator of apoptosis because its members integrate diverse survival and 
death signals into the mitochondrial membranes. In this family of proteins, members 
are sub-divided into anti-apoptotic members (such as Bcl-2, Bcl-xL, etc.) and 
pro-apoptotic members (such as Bax, Bad, etc.). Members from the two branches 
interact with each other and regulate different aspects of apoptosis. The 
well-characterized candidates such as Bcl-2 and Bax have been reported to be 
involved in mitochondrial membrane depolarization and thus facilitate the release of 
cytochrome c (Rosse et al., 1998). Having such an important role in the 
mitochondrion-mediated apoptosis, some better characterized members of the Bcl-2 
family were studied. They are the anti-apoptotic Bcl-2 and Bcl-xL, proapoptotic Bax, 
Bad and BimEL, as well as the linker of the two apoptotic pathways Bid. Out of our 
expectation, none of the Bcl-2 family proteins had significant change after the 
baicalein treatment, even after the prolonged 72 h incubation. This indicates that the 
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above Bcl-2 family proteins do not participate in the elicitation of the mitochondrial 
pathway, although we cannot exclude the possibility that other Bcl-2 proteins, which 
have been less-studied, may participate in the pathway. 
ROS has been recently identified to play a regulatory role in apoptosis (Ott et 
al,, 2007). Generation of intracellular ROS is unavoidable, yet problems arise only 
when the damaging ROS cannot be eradicated by the innate antioxidative systems, 
resulting in oxidative stress to the cells (Liu et al., 2002). Besides oxidizing the lipids 
in membranous structures and damaging DNA (Orrenius et al., 2007)，ROS also 
disturbs the normal mitochondrial proton gradient, causing loss of membrane 
potential and release of apoptogenic factors (Kowaltowski, 1996). Since the Bcl-2 
family proteins did not change after the baicalein treatment, we hypothesized that the 
mitochondrial dysfunction might be caused by other factors, including ROS. It was 
found that ROS was elevated in the baicalein-treated cells, and the antioxidant 
Trolox™ was able to eradicate the ROS produced inside the cells. Furthermore, the 
mitochondrial membrane depolarization and release of cytochrome c were also 
rescued by the antioxidant. The results suggested that ROS is al least one of the 
major regulators of the mitochondrial dysfunction in the baicalein-induced apoptosis. 
In conclusion, results from this study have proposed a comprehensive 
mechanism for the growth-inhibitory effect of baicalein on A375 cells. Baicalein 
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Chapter 6 
retards the cancer growth by first disturbing cell cycle progression by arresting the 
cells at S-phase. Prolonged cell cycle arrestment leads to apoptosis. Both the 
extrinsic and intrinsic apoptotic pathways are activated. In mediating the extrinsic 
pathway, baicalein elevates the death receptors DR4 and DR5 that enhanced 
activation of the initiator caspase-8. Later on, the initiator caspase-9 of the intrinsic 
pathway is also activated and ROS seems to be a regulator, that results in the 
mitochondrial membrane depolarization and cytochrome c release. The two pathways 
finally converge to into the activation of the effector caspase-3, PARP cleavage and 
DNA fragmentation (Fig. 5.1). Interestingly, the synergism between baicalein and 
TRAIL may allow the future development of this phytochemical as an adjuvant agent 
that can restore or enhance the TRAIL sensitivity, especially in those resistant cancer 
cells. Being an abundant and inexpensive, yet efficacious phytochemical, the 
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